# EDGAR Filing Document

**Accession Number:** 0001520262
**File Stem:** 0001193125-26-206534
**Filing Date:** 2026-5
**Character Count:** 189483
**Document Hash:** dd519d7d0ec2ff563b5300c20a9dde57
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-206534.hdr.sgml**: 20260505

**ACCESSION NUMBER**: 0001193125-26-206534

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 102

**CONFORMED PERIOD OF REPORT**: 20260331

**FILED AS OF DATE**: 20260505

**DATE AS OF CHANGE**: 20260505

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Alkermes plc.
- **CENTRAL INDEX KEY:** 0001520262
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 981007018
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35299
- **FILM NUMBER:** 26943766

**BUSINESS ADDRESS:**
- **STREET 1:** CONNAUGHT HOUSE
- **STREET 2:** 1 BURLINGTON ROAD
- **CITY:** DUBLIN 4
- **STATE:** L2
- **ZIP:** 00000
- **BUSINESS PHONE:** 00-353-1-772-8000

**MAIL ADDRESS:**
- **STREET 1:** CONNAUGHT HOUSE
- **STREET 2:** 1 BURLINGTON ROAD
- **CITY:** DUBLIN 4
- **STATE:** L2
- **ZIP:** 00000

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ANTLER SCIENCE TWO PLC
- **DATE OF NAME CHANGE:** 20110804

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Antler Science Two Ltd
- **DATE OF NAME CHANGE:** 20110509

?xml version='1.0' encoding='ASCII'? 10-Q

------

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form** 10-Q

**(Mark One)**

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the quarterly period ended** **March 31,** 2026

**OR**

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**Commission File Number** 001-35299

![img42436816_0.jpg](img42436816_0.jpg)

ALKERMES PUBLIC LIMITED COMPANY

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| Ireland | 98-1007018 |
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |

---

Connaught House

1 Burlington Road

Dublin 4**,** Ireland**,** D04 C5Y6

(Address of principal executive offices)

**+** 353**-**1-772-8000

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**Title of each class** | &nbsp;&nbsp;**Trading Symbol(s)** | &nbsp;&nbsp;**Name of each exchange on which registered** |
| &nbsp;&nbsp;Ordinary shares, $0.01 par value | &nbsp;&nbsp;ALKS | &nbsp;&nbsp;Nasdaq Global Select Market |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | |
|:---|:---|
| Large accelerated filer ☒ | Accelerated filer ☐ |
| Non-accelerated filer ☐ | Smaller reporting company ☐ |
|  | Emerging growth company ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of the registrant's ordinary shares, $0.01 par value, outstanding as of April 30, 2026 was 166,675,807 shares.

------

**ALKERMES PLC AND SUBSIDIARIES**

**QUARTERLY REPORT ON FORM 10-Q**

**FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2026**

---

| | | |
|:---|:---|:---|
|  |  | **Page No.** |
| &nbsp;&nbsp;[***<u>PART I - FINANCIAL INFORMATION</u>***](#part_i_financial_information) | &nbsp;&nbsp;[***<u>PART I - FINANCIAL INFORMATION</u>***](#part_i_financial_information) |  |
| &nbsp;&nbsp;Item 1.  | &nbsp;&nbsp;&nbsp;[<u>Condensed Consolidated Financial Statements (unaudited):</u>](#item_1_condensed_consolidated_financial_) |  |
|  | &nbsp;&nbsp;&nbsp;[<u>Condensed Consolidated Balance Sheets — March 31, 2026 and December 31, 2025</u>](#condensed_consolidated_balance_sheets) | 5 |
|  | &nbsp;&nbsp;&nbsp;[<u>Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income — For the Three Months Ended March 31, 2026 and 2025</u>](#condensed_consolidated_statements_operat) | 6 |
|  | &nbsp;&nbsp;&nbsp;[<u>Condensed Consolidated Statements of Cash Flows — For the Three Months Ended March 31, 2026 and 2025</u>](#condensed_consolidated_statements_cash_f) | 7 |
|  | &nbsp;&nbsp;&nbsp;[<u>Condensed Consolidated Statements of Shareholders' Equity — For the Three Months Ended March 31, 2026 and 2025</u>](#consolidated_statements_shareholders_equ) | 8 |
|  | &nbsp;&nbsp;&nbsp;[<u>Notes to Condensed Consolidated Financial Statements</u>](#notes_to_financial_statements) | 9 |
| &nbsp;&nbsp;Item 2. | &nbsp;&nbsp;&nbsp;[<u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>](#item2_managementsdiscussionandana_02424) | 27 |
| &nbsp;&nbsp;Item 3. | [<u>Quantitative and Qualitative Disclosures about Market Risk</u>](#item_3_quantitative_qualitative_disclosu) | 39 |
| &nbsp;&nbsp;Item 4. | [<u>Controls and Procedures</u>](#item_4_controls_procedures) | 39 |
| &nbsp;&nbsp;[***<u>PART II - OTHER INFORMATION</u>***](#part_ii_or_information) | &nbsp;&nbsp;[***<u>PART II - OTHER INFORMATION</u>***](#part_ii_or_information) |  |
| &nbsp;&nbsp;Item 1. | [<u>Legal Proceedings</u>](#item_1_legal_proceedings) | 40 |
| &nbsp;&nbsp;Item 1A. | [<u>Risk Factors</u>](#item_1a_risk_factors) | 40 |
| &nbsp;&nbsp;Item 2. | [<u>Unregistered Sales of Equity Securities and Use of Proceeds</u>](#item_2_unregistered_sales_equity_securit) | 40 |
| &nbsp;&nbsp;Item 5. | [<u>Other Information</u>](#item_5_or_information) | 40 |
| &nbsp;&nbsp;Item 6. | [<u>Exhibits</u>](#item_6_exhibits) | 41 |
| &nbsp;&nbsp;[<u>Signatures</u>](#signatures) | &nbsp;&nbsp;[<u>Signatures</u>](#signatures) | 42 |

---

------

**Cautionary Note Concerning Forward-Looking Statements**

This document contains and incorporates by reference "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). In some cases, these statements can be identified by the use of forward-looking terminology such as "may," "will," "could," "should," "would," "expect," "anticipate," "continue," "believe," "plan," "estimate," "intend" or other similar words. These statements discuss future expectations and contain projections of results of operations or of financial condition, or state trends and known uncertainties or other forward-looking information. Forward-looking statements in this Quarterly Report on Form 10-Q (this "Form 10-Q") may include, without limitation, statements regarding:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our expectations regarding our financial performance, including revenues, expenses, liquidity, capital expenditures, income taxes and profitability;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our expectations regarding our products, including expectations related to product development; regulatory exclusivities, filings, approvals and timelines; therapeutic and commercial value, scope and potential; and the costs and expenses related to such activities and expectations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our expectations regarding the timing, design and results of clinical trials of our products;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our expectations regarding the competitive, payer, legislative, regulatory and policy landscape, and changes therein, related to our products, including competition from generic forms of our products or competitive products and development programs; barriers to access or coverage of our products and potential changes in reimbursement of our products; and legislation, regulations, executive orders, guidance or other measures that may impact pricing and reimbursement of, and access to, our products;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our expectations regarding the financial impact of currency exchange rate fluctuations and valuations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our expectations regarding acquisitions, collaborations, licensing arrangements and other significant agreements with third parties, including those related to our products, development programs, and other business development opportunities;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our expectations regarding the impacts of new legislation, rules and regulations, the adoption of new accounting pronouncements, government shutdowns, or other global, political or economic changes, instability or disruptions;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our expectations regarding near-term changes in the nature of our market risk exposures or in our management's objectives and strategies with respect to managing such exposures;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our expectations regarding our ability to comply with restrictive covenants of our indebtedness and our ability to fund our debt service obligations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our expectations regarding future capital requirements and expenditures for our operations and our ability to finance such capital requirements and expenditures;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our expectations regarding the timing, outcome and impact of administrative, regulatory, legal and other proceedings related to our products and intellectual property ("IP"), including our patents, know-how, and related rights or obligations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our expectations regarding the Avadel Acquisition (as defined below), including any anticipated benefits and synergies of the transaction;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our expectations regarding the tax treatment and other anticipated benefits of the completed separation of our oncology business; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•other expectations discussed elsewhere in this Form 10-Q.

Actual results might differ materially from those expressed or implied by these forward-looking statements because these forward-looking statements are subject to risks, assumptions and uncertainties. In light of these risks, assumptions and uncertainties, the forward-looking expectations discussed in this Form 10-Q might not occur. You are cautioned not to place undue reliance on the forward-looking statements in this Form 10-Q, which speak only as of the date of this Form 10-Q. All subsequent written and oral forward-looking statements concerning the matters addressed in this Form 10-Q and attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. Except as required by applicable law or regulation, we do not undertake any obligation to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise. For information about the risks, assumptions and uncertainties of our business,

------

see "Part I, Item 1A—Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the United States ("U.S.") Securities and Exchange Commission (the "SEC") on February 25, 2026 (our "Annual Report").

This Form 10-Q may include data that we obtained from industry publications and third-party research, surveys and studies. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. While we believe that any industry publications and third-party research, surveys and studies from which data is included in this Form 10-Q are reliable, we have not independently verified any such data. This Form 10-Q may also include data based on our own internal estimates and research. Our internal estimates and research have not been verified by any independent source and are necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those described in "Part I, Item 1A—Risk Factors" in our Annual Report. These and other factors could cause our results to differ materially from those expressed or implied in this Form 10-Q.

**Note Regarding Company and Product References**

Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. We have a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including late-stage candidates in narcolepsy and idiopathic hypersomnia, and early-stage candidates in attention-deficit hyperactivity disorder ("ADHD") and fatigue associated with multiple sclerosis and Parkinson's disease. Use of terms such as "us," "we," "our," "Alkermes" or the "Company" in this Form 10-Q is meant to refer to Alkermes plc and its consolidated subsidiaries. Except as otherwise suggested by the context, (a) references to "products" or "our products" in this Form 10-Q include our marketed products, marketed products using our proprietary technologies, our licensed products, our product candidates and product candidates using our proprietary technologies, (b) references to the "biopharmaceutical industry" in this Form 10-Q are intended to include reference to the "biotechnology industry" and/or the "pharmaceutical industry" and (c) references to "licensees" in this Form 10-Q are used interchangeably with references to "partners."

**Note Regarding Trademarks**

We are the owner of various U.S. federal trademark registrations ("<sup>®</sup>") and other trademarks ("<sup>TM</sup>"), including ALKERMES<sup>®</sup>, ARISTADA<sup>®</sup>, ARISTADA INITIO<sup>®</sup>, LinkeRx<sup>®</sup>, LUMRYZ<sup>®</sup>, LYBALVI<sup>®</sup>, MICROPUMP<sup>®</sup>, NANOCRYSTAL<sup>®</sup> and VIVITROL<sup>®</sup>.

The following are trademarks of the respective companies listed: BYANNLI<sup>®</sup>, INVEGA<sup>®</sup>, INVEGA HAFYERA<sup>®</sup>, INVEGA SUSTENNA<sup>®</sup>, INVEGA TRINZA<sup>®</sup>, RISPERDAL CONSTA<sup>®</sup>, TREVICTA<sup>®</sup>, and XEPLION<sup>®</sup>—Johnson & Johnson or its affiliated companies; LLC; and VUMERITY<sup>®</sup>—Biogen MA Inc. (together with its affiliates, "Biogen"). Other trademarks, trade names and service marks appearing in this Form 10-Q are the property of their respective owners. Solely for convenience, the trademarks and trade names in this Form 10-Q may be referred to without the <sup>®</sup> or <sup>TM</sup> symbol, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto.

------

**PART I. FINANCIAL INFORMATION**

**Item 1. Condensed Consolidated Financial Statements:**

**ALKERMES PLC AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED BALANCE SHEETS**

**(unaudited)**

---

| | | |
|:---|:---|:---|
|  | **March 31, 2026** | **December 31, 2025** |
|  | **(In thousands, except share and per share amounts)** | **(In thousands, except share and per share amounts)** |
| **ASSETS** |  |  |
| CURRENT ASSETS: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $351551 | $388570 |
| &nbsp;&nbsp;&nbsp;&nbsp;Restricted cash |  | 731206 |
| &nbsp;&nbsp;&nbsp;&nbsp;Investments—short-term | 160311 | 199645 |
| &nbsp;&nbsp;&nbsp;&nbsp;Receivables, net | 407630 | 334025 |
| &nbsp;&nbsp;&nbsp;&nbsp;Inventory | 336703 | 196625 |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 102449 | 79090 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 1358644 | 1929161 |
| PROPERTY, PLANT AND EQUIPMENT, NET | 220587 | 221722 |
| INVESTMENTS—LONG-TERM | 26363 | 145 |
| RIGHT-OF-USE ASSETS | 78248 | 77209 |
| INTANGIBLE ASSETS, NET | 1784040 | 815 |
| GOODWILL | 596029 | 83027 |
| DEFERRED TAX ASSETS | 134808 | 125815 |
| OTHER ASSETS | 59357 | 49099 |
| TOTAL ASSETS | $4258076 | $2486993 |
| **LIABILITIES AND SHAREHOLDERS' EQUITY** |  |  |
| CURRENT LIABILITIES: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable and accrued expenses | $292579 | $289565 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued sales discounts, allowances and reserves | 272843 | 247126 |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating lease liabilities—short-term | 7577 | 6746 |
| &nbsp;&nbsp;&nbsp;&nbsp;Current portion of long-term debt | 26500 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 599499 | 543437 |
| OPERATING LEASE LIABILITIES—LONG-TERM | 63746 | 63253 |
| CONTINGENT CONSIDERATION | 109494 |  |
| LONG-TERM DEBT | 1483837 |  |
| DEFERRED TAX LIABILITIES | 181920 |  |
| OTHER LONG-TERM LIABILITIES | 68049 | 61008 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | 2506545 | 667698 |
| COMMITMENTS AND CONTINGENT LIABILITIES (Note 18) |  |  |
| SHAREHOLDERS' EQUITY: |  |  |
| &nbsp;&nbsp;&nbsp;Preferred shares, par value, $0.01 per share; 50,000,000 shares authorized; and zero issued and outstanding at March 31, 2026 and December 31, 2025, respectively. |  |  |
| &nbsp;&nbsp;&nbsp;Ordinary shares, par value, $0.01 per share; 450,000,000 shares authorized; 183,592,868 and 181,011,166 shares issued; and 166,462,299 and 165,607,028 shares outstanding at March 31, 2026 and December 31, 2025, respectively | 1836 | 1810 |
| &nbsp;&nbsp;&nbsp;Treasury shares, at cost (17,130,569 and 15,404,138 shares at March 31, 2026 and December 31, 2025, respectively) | (501425) | (450287) |
| &nbsp;&nbsp;&nbsp;&nbsp;Additional paid-in capital | 3055302 | 3004666 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated other comprehensive loss | (2908) | (2100) |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated deficit | (801274) | (734794) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total shareholders' equity | 1751531 | 1819295 |
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | $4258076 | $2486993 |

---

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

------

**ALKERMES PLC AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME**

**(unaudited)**

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** |
|  | **March 31,** | **March 31,** |
|  | **2026** | **2025** |
|  | **(In thousands, except per share amounts)** | **(In thousands, except per share amounts)** |
| REVENUES: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Product sales, net | $338114 | $244493 |
| &nbsp;&nbsp;&nbsp;&nbsp;Manufacturing and royalty revenues | 54797 | 62017 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total revenues | 392911 | 306510 |
| EXPENSES: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cost of goods manufactured and sold (exclusive of amortization of acquired intangible assets shown below) | 61578 | 49197 |
| &nbsp;&nbsp;&nbsp;&nbsp;Research and development | 103345 | 71817 |
| &nbsp;&nbsp;&nbsp;&nbsp;Selling, general and administrative | 264593 | 171704 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of acquired intangible assets | 11675 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total expenses | 441191 | 292718 |
| OPERATING (LOSS) INCOME | (48280) | 13792 |
| OTHER (EXPENSE) INCOME, NET: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest income | 8539 | 10141 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense | (20892) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Other (expense) income, net | (1293) | 1556 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other (expense) income, net | (13646) | 11697 |
| (LOSS) INCOME BEFORE INCOME TAXES | (61926) | 25489 |
| INCOME TAX PROVISION | 4554 | 3025 |
| NET (LOSS) INCOME | $(66480) | $22464 |
| (LOSS) EARNINGS PER ORDINARY SHARE: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Loss) earnings per ordinary share- basic | $(0.40) | $0.14 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Loss) earnings per ordinary share - diluted | $(0.40) | $0.13 |
| WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES OUTSTANDING: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic | 166196 | 163407 |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted | 166196 | 168737 |
| COMPREHENSIVE (LOSS) INCOME: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net (loss) income | $(66480) | $22464 |
| &nbsp;&nbsp;&nbsp;Holding (loss) gain, net of a tax (benefit) provision of $(171), and $168, respectively | (568) | 512 |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency translation loss | (240) |  |
| COMPREHENSIVE (LOSS) INCOME | $(67288) | $22976 |

---

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

------

**ALKERMES PLC AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

**(unaudited)**

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** |
|  | **March 31,** | **March 31,** |
|  | **2026** | **2025** |
|  | **(In thousands)** | **(In thousands)** |
| CASH FLOWS FROM OPERATING ACTIVITIES: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net (loss) income | $(66480) | $22464 |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjustments to reconcile net income to cash flows from operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 19429 | 7421 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of inventory step-up | 12726 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Share-based compensation expense | 36330 | 22810 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred income taxes | (8787) | 2507 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other non-cash charges | 1294 | 274 |
| &nbsp;&nbsp;&nbsp;&nbsp;Changes in assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Receivables | (23216) | 65825 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Contract assets |  | 1941 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventory | (6427) | (1751) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other assets | (16169) | (844) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Right-of-use assets | 2165 | 1840 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable and accrued expenses | (119472) | (1681) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued sales discounts, allowances and reserves | 748 | (22657) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Contract liabilities |  | 359 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating lease liabilities | (2773) | (2548) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other long-term liabilities | 4889 | 2851 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash flows (used in) provided by operating activities | (165743) | 98811 |
| CASH FLOWS FROM INVESTING ACTIVITIES: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Additions of property, plant and equipment | (4090) | (10110) |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from the sale of property, plant and equipment | 9 | 1713 |
| &nbsp;&nbsp;&nbsp;&nbsp;Business combination, net of cash acquired | (2085073) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Purchases of investments | (30454) | (95988) |
| &nbsp;&nbsp;&nbsp;&nbsp;Sales and maturities of investments | 42608 | 113487 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash flows (used in) provided by investing activities | (2077000) | 9102 |
| CASH FLOWS FROM FINANCING ACTIVITIES: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from the issuance of ordinary shares under share-based compensation arrangements | 15714 | 29528 |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from the issuance of debt, net | 1511557 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred financing costs paid to third-parties | (1614) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Employee taxes paid related to net share settlement of equity awards | (23442) | (28781) |
| &nbsp;&nbsp;&nbsp;&nbsp;Payment for the repurchase of ordinary shares | (27696) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash flows provided by financing activities | 1474519 | 747 |
| NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS | (768225) | 108660 |
| CASH, CASH EQUIVALENTS AND RESTRICTED CASH—Beginning of period | 1119776 | 291146 |
| CASH, CASH EQUIVALENTS AND RESTRICTED CASH—End of period | $351551 | $399806 |
| SUPPLEMENTAL CASH FLOW DISCLOSURE: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash paid for taxes | $1850 | $458 |
| &nbsp;&nbsp;&nbsp;&nbsp;Non-cash investing and financing activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purchased capital expenditures included in accounts payable and accrued expenses | $5556 | $5911 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unpaid deferred financing costs to third-parties | $1551 | $— |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unpaid contingent consideration | $107713 | $— |

---

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

------

**ALKERMES PLC AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY**

**(unaudited)**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Ordinary Shares** | **Ordinary Shares** | **Additional <br>Paid-In** | **Accumulated Other Comprehensive** | **Accumulated** | **Treasury Stock** | **Treasury Stock** |  |
|  | **Shares** | **Amount** | **Capital** | **(Loss) Income** | **Deficit** | **Shares** | **Amount** | **Total** |
|  | **(In thousands, except share data)** | **(In thousands, except share data)** | **(In thousands, except share data)** | **(In thousands, except share data)** | **(In thousands, except share data)** | **(In thousands, except share data)** | **(In thousands, except share data)** | **(In thousands, except share data)** |
| BALANCE — December 31, 2025 | 181011166 | $1810 | $3004666 | $(2100) | $(734794) | (15404138) | $(450287) | $1819295 |
| &nbsp;&nbsp;&nbsp;&nbsp;Issuance of ordinary shares under employee stock plans | 2581702 | 26 | 15688 |  |  |  |  | 15714 |
| &nbsp;&nbsp;&nbsp;&nbsp;Receipt of Alkermes' ordinary shares for the exercise of stock options or to satisfy minimum tax withholding obligations related to share-based awards |  |  |  |  |  | (730937) | (23442) | (23442) |
| &nbsp;&nbsp;&nbsp;&nbsp;Repurchase of Alkermes' ordinary shares |  |  |  |  |  | (995494) | (27696) | (27696) |
| &nbsp;&nbsp;&nbsp;&nbsp;Share-based compensation |  |  | 34948 |  |  |  |  | 34948 |
| &nbsp;&nbsp;&nbsp;Unrealized gain on marketable securities, net of tax benefit of $171 |  |  |  | (568) |  |  |  | (568) |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency translation loss |  |  |  | (240) |  |  |  | (240) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net loss |  |  |  |  | (66480) |  |  | (66480) |
| BALANCE — March 31, 2026 | 183592868 | $1836 | $3055302 | $(2908) | $(801274) | (17130569) | $(501425) | $1751531 |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Ordinary Shares** | **Ordinary Shares** | **Additional <br>Paid-In** | **Accumulated Other Comprehensive** | **Accumulated** | **Treasury Stock** | **Treasury Stock** |  |
|  | **Shares** | **Amount** | **Capital** | **(Loss) Income** | **Deficit** | **Shares** | **Amount** | **Total** |
|  | **(In thousands, except share data)** | **(In thousands, except share data)** | **(In thousands, except share data)** | **(In thousands, except share data)** | **(In thousands, except share data)** | **(In thousands, except share data)** | **(In thousands, except share data)** | **(In thousands, except share data)** |
| BALANCE — December 31, 2024 | 176670785 | $1767 | $2860890 | $(1967) | $(976458) | (14493791) | $(419255) | $1464977 |
| &nbsp;&nbsp;&nbsp;&nbsp;Issuance of ordinary shares under employee stock plans | 3510611 | 35 | 29493 |  |  |  |  | 29528 |
| &nbsp;&nbsp;&nbsp;&nbsp;Receipt of Alkermes' ordinary shares for the exercise of stock options or to satisfy minimum tax withholding obligations related to share-based awards |  |  |  |  |  | (834590) | (28781) | (28781) |
| &nbsp;&nbsp;&nbsp;&nbsp;Share-based compensation |  |  | 22883 |  |  |  |  | 22883 |
| &nbsp;&nbsp;&nbsp;Unrealized gain on marketable securities, net of tax provision of $168 |  |  |  | 512 |  |  |  | 512 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income |  |  |  |  | 22464 |  |  | 22464 |
| BALANCE — March 31, 2025 | 180181396 | $1802 | $2913266 | $(1455) | $(953994) | (15328381) | $(448036) | $1511583 |

---

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

------

**ALKERMES PLC AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Unaudited)**

**1. THE** **COMPANY**

Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. Alkermes has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including late-stage candidates in narcolepsy and idiopathic hypersomnia, and early-stage candidates in ADHD and fatigue associated with multiple sclerosis and Parkinson's disease. Headquartered in Ireland, Alkermes also has a corporate office and research and development ("R&D") center in Massachusetts and a manufacturing facility in Ohio.

On February 12, 2026 (the "Closing Date"), the Company completed the acquisition of Avadel Pharmaceuticals plc (now operating as Avadel Pharmaceuticals Limited) ("Avadel"), pursuant to the definitive transaction agreement entered into in October 2025 and subsequently amended in November 2025 (the "Transaction Agreement"), adding both LUMRYZ to the Company's portfolio of proprietary commercial products and a commercial organization with experience in narcolepsy. Pursuant to the Transaction Agreement, the Company acquired the entire issued and to be issued ordinary share capital of Avadel for consideration of (i) $21.00 per ordinary share, nominal value $0.01 per share, of Avadel (each, an "Avadel Share"), payable in cash at closing and (ii) a non-transferable contingent value right (the "CVR") entitling holders of Avadel Shares to a potential additional cash payment of $1.50 per Avadel Share, contingent upon achievement of a certain specified milestone (the "Avadel Acquisition").

**2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

*Basis of Presentation*

The accompanying condensed consolidated financial statements of the Company for the three months ended March 31, 2026 and 2025 are unaudited and have been prepared on a basis substantially consistent with the audited financial statements for the year ended December 31, 2025. The year-end consolidated balance sheet data, which is presented for comparative purposes, was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the U.S. (commonly referred to as "GAAP"). In the opinion of management, the condensed consolidated financial statements include all adjustments of a normal recurring nature that are necessary to state fairly the results of operations for the reported periods.

The accompanying condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto of the Company, which are contained in the Annual Report. The results of the Company's operations for any interim period are not necessarily indicative of the results of the Company's operations for any other interim period or for any full fiscal year.

*Principles of Consolidation*

The accompanying condensed consolidated financial statements include the accounts of Alkermes plc and its wholly-owned subsidiaries as disclosed in Note 2, *Summary of Significant Accounting Policies* in the "Notes to Consolidated Financial Statements" accompanying the Annual Report. Intercompany accounts and transactions have been eliminated. Columns and rows within tables may not sum due to rounding.

*Use of Estimates*

The preparation of the Company's condensed consolidated financial statements in accordance with GAAP requires that Company management make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates, judgments and methodologies, including, but not limited to, those related to revenue from contracts with its customers and related allowances, impairment and amortization of intangibles and long-lived assets, inventory, share-based compensation, income taxes including the valuation allowance for deferred tax assets, valuation of the Avadel Acquisition, investments, contingent consideration and litigation. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different conditions or using different assumptions.

------

**ALKERMES PLC AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Unaudited) (Continued)**

*Business Combinations* 

In accordance with the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") 805, *Business Combinations* ("Topic 805"), acquisitions that meet the definition of a business are recorded using the acquisition method of accounting. The Company recognizes and measures the identifiable assets acquired, liabilities assumed and any non-controlling interest as of the acquisition date at fair value. The excess, if any, of the fair value of total consideration transferred in a business combination over the fair value of identifiable assets acquired, liabilities assumed and any non-controlling interest is recognized as goodwill. Transaction costs incurred as a result of a business combination other than costs related to the issuance of debt or equity securities are recorded in the period the costs are incurred.

*Contingent Consideration* 

Contingent consideration in a business combination may consist of development, regulatory and/or commercial milestone payments and is included as part of the acquisition cost and recognized at fair value as of the acquisition date. Fair value is generally estimated by using a probability-weighted discounted cash flow approach resulting from contingent consideration and is re-measured at each reporting date until the contingency is resolved. Changes in fair value are recognized within "Operating (loss) income" in the accompanying condensed consolidated statements of operations and comprehensive (loss) income.

*Reclassification*

The Company reclassified certain prior year amounts on the consolidated balance sheet to conform to the current year presentation. These reclassifications had no impact on the previously reported total assets, liabilities or shareholders' equity.

*Intangible Assets*

Intangible assets acquired in business combinations, including developed technology, product rights, licenses, and in-process research and development ("IPR&D"), are recorded at fair value as of the acquisition date. Definite-lived identifiable intangible assets are amortized based on the proportion of expected excess earnings over their estimated economic useful life. This method reflects the pattern in which the economic benefits of the intangible assets are expected to be realized.

Acquired IPR&D projects that have not yet received regulatory approval are considered indefinite-lived intangible assets and are required to be capitalized as indefinite-lived intangible assets until completion of the IPR&D project or abandonment. IPR&D projects are not amortized but are tested annually for impairment or more frequently if indicators arise. Upon completion of the development project, an impairment assessment is performed prior to amortizing the asset over its estimated useful life. IPR&D assets related to abandoned IPR&D projects are fully impaired.

*Segment Information*

Operating segments are defined as components of an enterprise engaging in business activities for which separate financial information is available and regularly reviewed by the chief operating decision maker ("CODM") in deciding how to allocate resources and in assessing performance. The Company has utilized the management approach to determine that the Company is managed as one segment on a consolidated basis and is in the business of developing, manufacturing and commercializing medicines designed to help people living with complex and difficult-to-treat psychiatric and neurological disorders. The Company's CODM, the Chairman and Chief Executive Officer, reviews the Company's operating results on an aggregate basis and manages the Company's operations as a single operating unit. The Company's CODM measures profitability on a reportable segment basis using net income and utilizes this information in allocating resources and in assessing performance by monitoring budget versus actual results. Please refer to Note 17, *Segment Reporting*, in these "Notes to Condensed Consolidated Financial Statements" in this Form 10-Q for further information.

*New Accounting Pronouncements*

From time to time, new accounting pronouncements are issued by the FASB or other standard-setting bodies that are adopted by the Company on or prior to the specified effective date. Unless otherwise described in this Form 10-Q, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.

------

**ALKERMES PLC AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Unaudited) (Continued)**

In November 2024, the FASB issued Accounting Standards Update ("ASU") 2024-03, *Income Statement—Reporting Comprehensive Income-Expense Disaggregation Disclosures*, to improve disclosures about a public business entity's expenses and address requests from investors for more detailed information about the types of expenses (including purchases of inventory, employee compensation, depreciation, amortization and depletion) in commonly-presented expense captions, such as cost of sales, selling, general and administrative expenses, and research and development. All disclosure requirements under this guidance are required for public business entities and effective for annual periods beginning after December 15, 2026 and interim periods beginning after December 15, 2027. Early adoption is permitted and the amendments in this guidance will be applied prospectively to financial statements for periods after the effective dates. The Company is currently evaluating the impact this ASU will have on its consolidated financial statements and related disclosures.

In September 2025, the FASB issued ASU 2025-06, *Targeted Improvements to the Accounting for Internal-Use Software.* This ASU updates the requirements for capitalization of internal-use software, removing all reference to prescriptive and sequential software development stages (referred to as "project stages"). This ASU is effective for annual periods beginning after December 15, 2027, and for interim periods within those fiscal years. The Company is currently assessing the impact this ASU will have on its consolidated financial statements and related disclosures.

In December 2025, the FASB issued ASU 2025-11, *Interim Reporting*. The amendments in this update clarify current interim disclosure requirements and provide a comprehensive list of required interim disclosures. The update also incorporates a disclosure principle that requires entities to disclose events that occur after the end of the reporting period. This update is effective for interim periods within annual periods beginning after December 15, 2027, though early adoption is permitted. The Company is currently assessing the impact this ASU will have on its consolidated financial statements and related disclosures.

**3. BUSINESS COMBINATION**

*Acquisition of Avadel Pharmaceuticals plc*

On February 12, 2026, the Company successfully completed the Avadel Acquisition, adding both LUMRYZ to the Company's proprietary commercial products and a commercial organization with experience in narcolepsy. Pursuant to the Transaction Agreement, the Company acquired all of the issued and outstanding Avadel Shares for $21.00 per share in cash and a non-transferable CVR entitling holders of Avadel Shares to a potential additional cash payment of $1.50 per Avadel Share, contingent upon achievement of a certain specified milestone (the "CVR Milestone").

Contingent payments of up to $165.7 million may become due to former Avadel shareholders upon the achievement of the CVR Milestone. In connection therewith, the Company recorded a contingent consideration liability of $107.7 million as of the Closing Date to reflect the estimated fair value of such contingent consideration. The estimated fair value of the contingent consideration was determined under an income approach using a Probability-Weighted Discounted Cash Flow Model ("DCF"). The key assumptions considered include probability of milestone achievement and estimated discount rates. At each reporting period after the Avadel Acquisition, the Company will revalue the contingent consideration liability and will record increases or decreases in the fair value of the liability in its condensed consolidated statements of operations and comprehensive (loss) income. Changes in fair value will result from changes in actual and projected achievement of the CVR Milestone, as well as changes to the discount rate. The change in the fair value of the contingent consideration from the Closing Date through March 31, 2026 was not material.

In connection with the Avadel Acquisition, the vesting of certain outstanding Avadel equity awards was accelerated as of the Closing Date and each vested Avadel equity award became entitled to receive cash consideration and the right to receive one CVR per Avadel Share. The purchase price for the Avadel Acquisition includes $134.9 million related to Avadel Shares for which vesting was accelerated in connection with the acquisition and is attributable to pre-combination service. The Company recognized share-based compensation expense of $20.2 million during the three months ended March 31, 2026 related to the acceleration of unvested share-based compensation awards attributable to post-combination service and the fair value related to the contingent CVR payment that could be made to former Avadel employees as of the Closing Date.

The Avadel Acquisition has been accounted for as a business combination, using the acquisition method of accounting in accordance with Topic 805. The acquisition method requires, among other things, that assets acquired and liabilities assumed in a business combination be recognized at their fair values as of the acquisition date.

------

**ALKERMES PLC AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Unaudited) (Continued)**

The Company's purchase price allocation is preliminary and based on the information available as of the reporting date. The Company's estimates and assumptions are subject to refinement as the Company continues to review information related to the Avadel Acquisition. The Company remains in the process of reviewing and finalizing the measurement of certain assets acquired and liabilities assumed, including but not limited to: tax positions, and other tax-related matters, and the estimated fair values of acquired intangible assets and inventory. Adjustments to the valuation of assets acquired and liabilities assumed will result in a corresponding adjustment to goodwill. The Company expects to complete the purchase price allocation as soon as practicable, but no later than one year from the Closing Date.

The total preliminary purchase consideration related to the Avadel Acquisition was as follows:

---

| | |
|:---|:---|
| **(In thousands)** | **Amount** |
| &nbsp;&nbsp;&nbsp;Cash consideration paid for Avadel's ordinary shares | $2064310 |
| &nbsp;&nbsp;&nbsp;Cash consideration paid for cash settlement of Avadel equity awards | 134897 |
| &nbsp;&nbsp;&nbsp;Fair value of CVR contingent consideration | 107713 |
| Total preliminary purchase consideration | $2306920 |

---

The following table summarizes the preliminary estimates of the fair value of assets acquired and liabilities assumed as of the Closing Date:

---

| | |
|:---|:---|
| **(In thousands)** | **February 12, 2026** |
| **Acquired Assets:** |  |
| &nbsp;&nbsp;Cash and cash equivalents | $114135 |
| &nbsp;&nbsp;Receivables | 50389 |
| &nbsp;&nbsp;Inventory | 147323 |
| &nbsp;&nbsp;Prepaid expenses and other current assets | 13483 |
| &nbsp;&nbsp;Property, plant and equipment | 796 |
| &nbsp;&nbsp;Right-of-use assets | 2297 |
| &nbsp;&nbsp;Intangible assets | 1794900 |
| &nbsp;&nbsp;Deferred tax assets | 1244 |
| &nbsp;&nbsp;Other assets | 6551 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total fair value of assets acquired | $2131118 |
| **Assumed Liabilities:** |  |
| &nbsp;&nbsp;Accounts payable and accrued expenses | $124654 |
| &nbsp;&nbsp;Accrued sales discounts, allowances and reserves | 24969 |
| &nbsp;&nbsp;Operating lease liabilities | 2296 |
| &nbsp;&nbsp;Deferred tax liability | 183129 |
| &nbsp;&nbsp;Other long-term liabilities | 2152 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total recognized identifiable net assets acquired and liabilities assumed | $1793918 |
| &nbsp;&nbsp;Goodwill | 513002 |
| &nbsp;&nbsp;&nbsp;&nbsp;Preliminary fair value of total consideration | $2306920 |
| &nbsp;&nbsp;Contingent consideration | 107713 |
| **Total Cash Consideration Paid** | $2199207 |

---

*Acquired Inventory*

The fair value of the acquired inventory was estimated using the comparative sales method, which estimated the expected sales price of the product, reduced by all costs expected to be incurred to complete or to dispose of the inventory, as well as a market-participant profit allowance.

------

**ALKERMES PLC AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Unaudited) (Continued)**

*Acquired Intangible Assets*

The identifiable intangible assets acquired included the following:

---

| | |
|:---|:---|
| **(In thousands)** |  |
| LUMRYZ | $1768600 |
| In-process research and development | 26300 |
| &nbsp;&nbsp;Total identifiable intangible assets | $1794900 |

---

The fair value of LUMRYZ was estimated based on a multi-period excess earnings method which calculates the present value of the estimated revenues and net cash flows derived from LUMRYZ. Amortization of LUMRYZ is calculated using the percentage of excess earnings over the economic useful life method. The IPR&D relates to the product candidate acquired in the Avadel Acquisition, valiloxybate. Due to the early stage of development of this asset, and given the proximity to the Closing Date of a license agreement entered into by Avadel related to valiloxybate and the lack of suitable market comparables, the valuation was prepared utilizing a cost approach consisting of the upfront payment under the license agreement, together with additional development costs incurred by Avadel through prior to the Closing Date in respect of valiloxybate.

*Deferred Tax Liabilities*

The deferred tax liability of $183.1 million relates to the tax effect of the difference between the fair value and tax basis of acquired intangible assets owned by an Irish subsidiary of the Company. The deferred tax asset of $1.2 million relates to the tax effect of acquired net operating losses and temporary differences, partially offset by the difference between the fair value and tax basis of acquired intangible assets and inventory owned by a U.S. subsidiary of the Company.

*Goodwill*

The excess of the estimated fair value of the purchase price consideration over the fair value amounts assigned to the assets acquired and liabilities assumed represents the goodwill amount resulting from the Avadel Acquisition. The factors that contributed to the recognition of goodwill included the synergies that are specific to the Company's business and not available to market participants, including the acquisition of a commercial organization with experience in narcolepsy which accelerates the Company's commercial entry into the sleep medicine market and provides a strong foundation for the potential launch of alixorexton, the Company's lead orexin development candidate. Goodwill is not deductible for tax purposes.

*Revenues and Net (Loss) Income of Avadel*

The operations of Avadel for the period of the Closing Date through March 31, 2026 have been included in the Company's condensed consolidated statements of operations and comprehensive (loss) income for the quarter ended March 31, 2026. Total revenues of $39.5 million and net income of $16.2 million were recorded for this period.

*Transaction Costs*

In conjunction with the Avadel Acquisition, the Company incurred approximately $34.8 million of transaction costs during the three months ended March 31, 2026, all of which were recognized as selling, general and administrative in the unaudited condensed consolidated statements of operations and comprehensive (loss) income. There were no transaction costs for the Avadel Acquisition incurred during the three months ended March 31, 2025.

*Pro forma financial information (unaudited)*

The following unaudited pro forma information presents the combined results of operations for the three months ended March 31, 2026 and 2025 as if the Avadel Acquisition had been completed on January 1, 2025. The unaudited pro forma financial information is based on the historical financial information for the Company and Avadel, along with certain pro forma adjustments described below. The unaudited pro forma information for the three months ended March 31, 2026 reflects revenues and net loss of Avadel from January 1, 2026 through the Closing Date, and excludes approximately $77.7 million of direct one-time transaction costs incurred by Avadel. The following unaudited pro forma information has been prepared for comparative purposes only and is not necessarily indicative of the results of operations had the Avadel Acquisition occurred on the assumed date, nor is it necessarily an indication of future operating results.

------

**ALKERMES PLC AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Unaudited) (Continued)**

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| **(In thousands)** | **2026** | **2025** |
| Revenues | $425740 | $359021 |
| Net loss | (35860) | (125578) |

---

The unaudited pro forma financial information includes, where applicable, adjustments primarily for:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)increased amortization expense related to the LUMRYZ intangible asset acquired;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)increased costs of goods manufactured and sold related to the amortization of inventory fair value adjustments;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)increased interest expense to reflect the borrowings under the Facilities (as defined in Note 12, *Long-Term Debt* in these "Notes to Condensed Consolidated Financial Statements"), including the interest and amortization of deferred financing costs, net of reversal of historical interest expense and loss on extinguishment of Avadel's royalty financing obligation;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)adjustment of approximately $44.5 million in direct one-time acquisition transaction costs, including $9.7 million recognized in fiscal year 2025, from the periods incurred to the period these expenses would have been recognized given the assumed transaction date identified above;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)adjustment of $20.2 million related to the acceleration of unvested share-based compensation awards attributable to post-combination service and the fair value related to the contingent CVR payment that could be made to former Avadel employees if the specified CVR milestone is met, from the period incurred to the periods in which these expenses would have been recognized with the assumed transaction date identified above; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi)the related income tax effects of these adjustments to the income tax provision for the Company.

The unaudited pro forma information does not reflect the cost of any integration activities, benefits from any synergies that may be derived from the Avadel Acquisition or revenue growth that may be anticipated.

**4. REVENUE FROM CONTRACTS WITH CUSTOMERS**

The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which it expects to receive in exchange for those goods or services. The Company recognizes revenue following the five-step model prescribed in accordance with FASB ASC 606, *Revenue from Contracts with Customers*, or Topic 606: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligations.

<u>Product Sales, Net</u>

The Company's product sales, net consist of sales in the U.S. of ARISTADA and ARISTADA INITIO, LYBALVI, VIVITROL, and, following the completion of the Avadel Acquisition on February 12, 2026, LUMRYZ, primarily to wholesalers, specialty distributors and specialty pharmacies. Product sales, net are recognized when the customer obtains control of the product, which is when the product has been received by the customer.

During the three months ended March 31, 2026 and 2025, the Company recorded product sales, net, as follows:

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| **(In thousands)** | **2026** | **2025** |
| &nbsp;&nbsp;&nbsp;VIVITROL | $112434 | $100996 |
| &nbsp;&nbsp;&nbsp;ARISTADA and ARISTADA INITIO | 93824 | 73475 |
| &nbsp;&nbsp;&nbsp;LYBALVI | 92364 | 70022 |
| &nbsp;&nbsp;&nbsp;LUMRYZ | 39492 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total product sales, net | $338114 | $244493 |

---

------

**ALKERMES PLC AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Unaudited) (Continued)**

Revenues from product sales are recorded net of reserves established for applicable discounts and allowances that are offered within contracts with the Company's customers, healthcare providers or payers. The Company's process for estimating reserves established for these variable consideration components does not differ materially from historical practices. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Actual amounts may ultimately differ from the Company's estimates. If actual results vary, the Company adjusts these estimates, which could have an effect on earnings in the period of adjustment. See the "Revenue from Contracts with Customers" section in Note 2, *Summary of Significant Accounting Policies* in the "Notes to Consolidated Financial Statements" in the Annual Report for information with respect to the Company's significant categories of sales discounts and allowances.

The decrease in Medicaid rebates as a percentage of sales was primarily due to gross-to-net favorability, as actual Medicaid rebates related to VIVITROL, ARISTADA/ARISTADA INITIO and LYBALVI were lower than original estimates by approximately $5.4 million, $2.8 million and $0.5 million, respectively.

A rollforward of the Company's provisions for sales discounts and allowances is as follows:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **March 31, 2026** | **March 31, 2026** | **March 31, 2026** | **March 31, 2026** | **March 31, 2026** |
| **(In thousands)** | **Contractual Adjustments**<sup>(2)</sup> | **Discounts**<sup>(3)</sup> | **Product Returns** | **Other** | **Total** |
| Beginning balance — December 31, 2025 | $211440 | $41327 | $55455 | $7813 | $316035 |
| Avadel beginning balance as of February 12, 2026 <sup>(1)</sup> | 1475 | 2642 | 724 | 24180 | 29021 |
| &nbsp;&nbsp;Current provisions relating to sales in current year | 146144 | 111269 | 6518 | 39093 | 303024 |
| &nbsp;&nbsp;Adjustments relating to prior years | (8772) | (5347) | (674) | 286 | (14507) |
| &nbsp;&nbsp;Payments relating to sales in current year | (11666) | (100040) |  | (27272) | (138978) |
| &nbsp;&nbsp;Payments relating to sales in prior years | (124102) | (14947) | (3197) | (12743) | (154989) |
| Ending balance — March 31, 2026 | $214519 | $34904 | $58826 | $31357 | $339606 |

---

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)Amounts consist of beginning balance as of the Closing Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)"Contractual Adjustments" include "Medicaid Rebates" and "Medicare Part D" accruals.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)"Discounts" include "Chargebacks" and "Product Discounts."

Total revenue-related reserves as of March 31, 2026 and December 31, 2025 included in the accompanying consolidated balance sheets are summarized as follows:

---

| | | |
|:---|:---|:---|
|  | **March 31,** | **December 31,** |
| **(In thousands)** | **2026** | **2025** |
| Reduction of accounts receivable | $16249 | $21049 |
| Components of accrued sales discounts, allowances and reserves | 272843 | 247126 |
| Components of other long-term liabilities | 50514 | 47860 |
| Total revenue-related reserves | $339606 | $316035 |

---

<u>Manufacturing and Royalty Revenues</u>

During the three months ended March 31, 2026 and 2025, the Company recorded manufacturing and royalty revenues from its collaboration arrangements as follows:

---

| | | | |
|:---|:---|:---|:---|
|  | **Three Months Ended March 31, 2026** | **Three Months Ended March 31, 2026** | **Three Months Ended March 31, 2026** |
| **(In thousands)** | **Manufacturing<br>Revenue** | **Royalty<br>Revenue** | **Total** |
| Long-acting INVEGA products<sup>(1)</sup> | $— | $17995 | $17995 |
| VUMERITY |  | 27349 | 27349 |
| Other | 4068 | 5385 | 9453 |
|  | $4068 | $50729 | $54797 |

---

------

**ALKERMES PLC AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Unaudited) (Continued)**

---

| | | | |
|:---|:---|:---|:---|
|  | **Three Months Ended March 31, 2025** | **Three Months Ended March 31, 2025** | **Three Months Ended March 31, 2025** |
| **(In thousands)** | **Manufacturing<br>Revenue** | **Royalty<br>Revenue** | **Total** |
| Long-acting INVEGA products<sup>(1)</sup> | $— | $17745 | $17745 |
| VUMERITY | 5975 | 21858 | 27833 |
| Other | 11352 | 5087 | 16439 |
|  | $17327 | $44690 | $62017 |

---

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)"long-acting INVEGA products": INVEGA SUSTENNA/XEPLION (paliperidone palmitate), INVEGA TRINZA/TREVICTA (paliperidone palmitate) and INVEGA HAFYERA/BYANNLI (paliperidone palmitate). The Company's royalty on net sales of INVEGA SUSTENNA in the U.S. expired in August 2024.

**5. INVESTMENTS**

Investments consist of the following (in thousands):

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  |  | **Gross Unrealized** | **Gross Unrealized** | **Gross Unrealized** |  |
|  |  |  | **Losses** | **Losses** |  |
|  | **Amortized** |  | **Less than** | **Greater than** | **Estimated** |
| **March 31, 2026** | **Cost** | **Gains** | **One Year** | **One Year** | **Fair Value** |
| Short-term investments: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Available-for-sale securities: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. government and agency debt securities | $67931 | $117 | $(20) | $— | $68028 |
| &nbsp;&nbsp;&nbsp;&nbsp;Corporate debt securities | 92166 | 186 | (69) |  | 92283 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total short-term investments | 160097 | 303 | (89) |  | 160311 |
| Long-term investments: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Available-for-sale securities: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. government and agency debt securities | 15044 |  | (37) |  | 15007 |
| &nbsp;&nbsp;&nbsp;&nbsp;Corporate debt securities | 11255 |  | (44) |  | 11211 |
|  | 26299 |  | (81) |  | 26218 |
| &nbsp;&nbsp;&nbsp;Held-to-maturity securities: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Certificates of deposit | 145 |  |  |  | 145 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total long-term investments | 26444 |  | (81) |  | 26363 |
| Total investments | $186541 | $303 | $(170) | $— | $186674 |
| **December 31, 2025** |  |  |  |  |  |
| Short-term investments: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Available-for-sale securities: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. government and agency debt securities | $101033 | $338 | $— | $— | $101371 |
| &nbsp;&nbsp;&nbsp;&nbsp;Corporate debt securities | 97740 | 534 |  |  | 98274 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total short-term investments | 198773 | 872 |  |  | 199645 |
| &nbsp;&nbsp;&nbsp;Held-to-maturity securities: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Certificates of deposit | 145 |  |  |  | 145 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total long-term investments | 145 |  |  |  | 145 |
| Total investments | $198918 | $872 | $— | $— | $199790 |

---

At March 31, 2026, the Company's investments in corporate debt securities had a minimum rating of A2 (Moody's)/A (Standard and Poor's), and 47 of the Company's 120 investment securities were in an unrealized loss position with an aggregate estimated fair value of $83.4 million. The primary reason these securities were in an unrealized loss position is that they are fixed-rate securities that were acquired in a rising interest rate environment. In making the determination whether the decline in fair value of these securities was temporary, the Company evaluated whether it intended to sell the security and whether it was more likely than not that the Company would be required to sell the security before recovering its amortized cost basis. The Company has the intent and ability to hold these investments until recovery, which may be at maturity.

------

**ALKERMES PLC AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Unaudited) (Continued)**

Realized gains and losses on the sales and maturities of investments, which were identified using the specific identification method, were as follows:

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| **(In thousands)** | **2026** | **2025** |
| Proceeds from the sales and maturities of investments | $42608 | $113487 |
| Realized gains | $1 | $1 |
| Realized losses | $— | $— |

---

The Company's available-for-sale and held-to-maturity securities at March 31, 2026 had contractual maturities in the following periods:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Available-for-sale** | **Available-for-sale** | **Held-to-maturity** | **Held-to-maturity** |
|  | **Amortized** | **Estimated** | **Amortized** | **Estimated** |
| **(In thousands)** | **Cost** | **Fair Value** | **Cost** | **Fair Value** |
| Within 1 year | $113728 | $113778 | $145 | $145 |
| After 1 year through 5 years | 72668 | 72751 |  |  |
| &nbsp;&nbsp;&nbsp;Total | $186396 | $186529 | $145 | $145 |

---

**6. FAIR VALUE**

The following table presents information about the Company's assets and liabilities that are measured at fair value on a recurring basis and indicates the fair value hierarchy and the valuation techniques that the Company utilized to determine such fair value:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **March 31,** |  |  |  |
| **(In thousands)** | **2026** | **Level 1** | **Level 2** | **Level 3** |
| **Assets:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Cash equivalents | $7960 | $7960 | $— | $— |
| &nbsp;&nbsp;&nbsp;U.S. government and agency debt securities | 83035 | 78676 | 4359 |  |
| &nbsp;&nbsp;&nbsp;Corporate debt securities | 103494 |  | 102994 | 500 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total | $194489 | $86636 | $107353 | $500 |
| **Liabilities:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Contingent consideration | $109494 |  |  | 109494 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total | $109494 | $— | $— | $109494 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **December 31,** |  |  |  |
|  | **2025** | **Level 1** | **Level 2** | **Level 3** |
| **Assets:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Cash equivalents | $18583 | $18583 | $— | $— |
| &nbsp;&nbsp;&nbsp;U.S. government and agency debt securities | 101371 | 94246 | 7125 |  |
| &nbsp;&nbsp;&nbsp;Corporate debt securities | 98274 |  | 97774 | 500 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total | $218228 | $112829 | $104899 | $500 |

---

The Company transfers its financial assets and liabilities, measured at fair value on a recurring basis, between the fair value hierarchies at the end of each reporting period. There were no transfers of any securities between levels during the three months ended March 31, 2026. At March 31, 2026, the contingent consideration resulting from the Avadel Acquisition was valued as a contingent liability utilizing Level 3 inputs as its fair value is based on significant inputs not observable in the market.

------

**ALKERMES PLC AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Unaudited) (Continued)**

The following table is a rollforward of the fair value of the Company's assets with fair values that were determined using Level 3 inputs at March 31, 2026:

---

| | | |
|:---|:---|:---|
|  | **Fair Value** | **Fair Value** |
| **(In thousands)** | **Assets** | **Liabilities** |
| Balance, January 1, 2026 | $500 | $— |
| &nbsp;&nbsp;Addition of contingent consideration related to CVR Milestone for consideration transferred |  | 107713 |
| &nbsp;&nbsp;Addition of contingent consideration related to CVR Milestone for post-combination expense |  | 1781 |
| Balance, March 31, 2026 | $500 | $109494 |

---

The Company's investments classified as Level 2 within the fair value hierarchy were initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing market-observable data. The market-observable data included reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers, current spot rates and other industry and economic events. The Company validated the prices developed using the market-observable data by obtaining market values from other pricing sources, analyzing pricing data in certain instances and confirming that the relevant markets are active. For additional information related to the Company's contingent consideration, see Note 18, *Commitments and Contingent Liabilities* in these "Notes to Condensed Consolidated Financial Statements".

The carrying amounts reflected in the accompanying condensed consolidated balance sheets for cash and cash equivalents, accounts receivable, contract assets, other current assets, accounts payable and accrued expenses, sales discounts, allowances and reserves approximate fair value due to their short-term nature.

The estimated fair value of the Company's long-term debt under its Facilities (as defined in Note 12, *Long-Term Debt* in these "Notes to Condensed Consolidated Financial Statements"), which was based on quoted market price indications (Level 2 in the fair value hierarchy) and which may not be representative of actual values that could have been, or will be, realized in the future, was $1,542.6 million at March 31, 2026.

**7. INVENTORY**

Inventory is stated at the lower of cost and net realizable value. Cost is determined using the first-in, first-out method. Inventory consists of the following:

---

| | | |
|:---|:---|:---|
|  | **March 31,** | **December 31,** |
| **(In thousands)** | **2026** | **2025** |
| Raw materials | $70966 | $68387 |
| Work in process | 120844 | 90498 |
| Finished goods<sup>(1)</sup> | 144893 | 37740 |
| &nbsp;&nbsp;&nbsp;Total inventory | $336703 | $196625 |

---

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)At March 31, 2026 and December 31, 2025, the Company had $26.2 million and $31.7 million, respectively, of finished goods inventory located at its third-party warehouse and shipping service provider.

In connection with the Avadel Acquisition, the Company recorded a fair value step-up adjustment to inventory of $121.6 million, consisting of approximately $19.1 million and $102.5 million in work in process and finished goods, respectively. The inventory step-up is being amortized when inventory is sold to customers, substantially all of which is expected to be within a year of the Closing Date. During the three months ended March 31, 2026, the Company amortized $12.7 million in inventory step-up within "Cost of goods manufactured and sold" in the accompanying condensed consolidated statement of operations and comprehensive (loss) income.

------

**ALKERMES PLC AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Unaudited) (Continued)**

**8. PROPERTY, PLANT AND EQUIPMENT**

Property, plant and equipment consist of the following:

---

| | | |
|:---|:---|:---|
|  | **March 31,** | **December 31,** |
| **(In thousands)** | **2026** | **2025** |
| Land | $957 | $957 |
| Building and improvements | 152112 | 150672 |
| Furniture, fixtures and equipment | 259014 | 255773 |
| Leasehold improvements | 59900 | 42535 |
| Construction in progress | 23829 | 38795 |
| &nbsp;&nbsp;&nbsp;Subtotal | 495812 | 488732 |
| Less: accumulated depreciation | (275225) | (267010) |
| &nbsp;&nbsp;&nbsp;Total property, plant and equipment, net | $220587 | $221722 |

---

**9. GOODWILL AND INTANGIBLE ASSETS** 

Goodwill and intangible assets consist of the following:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  |  | **March 31, 2026** | **March 31, 2026** | **March 31, 2026** | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** |
| **(In thousands)** | **Weighted Amortizable Life (Years)** | **Gross Carrying Amount** | **Accumulated Amortization** | **Net Carrying Amount** | **Gross Carrying Amount** | **Accumulated Amortization** | **Net Carrying Amount** |
| Goodwill |  | $596029 | $— | $596029 | $83027 | $— | $83027 |
| Definite-lived intangible assets: |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;LUMRYZ | 14 | $1768600 | $(11651) | $1756949 | $— | $— | $— |
| &nbsp;&nbsp;&nbsp;&nbsp;Capitalized IP | 12 | 1000 | (209) | 791 | 1000 | (185) | 815 |
| Indefinite-lived intangible asset: |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;IPR&D |  | 26300 |  | 26300 |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total |  | $1795900 | $(11860) | $1784040 | $1000 | $(185) | $815 |

---

Based on its most recent analysis, the Company expects to amortize approximately $79.8 million, $103.7 million, $125.5 million, $117.9 million and $115.6 million of its definite-lived intangible asset in the years ending December 31, 2026 through 2030, respectively. Although the Company believes such expectations are reasonable, given the inherent risks and uncertainties underlying its expectations regarding future revenues, there is the potential for the Company's actual results to vary significantly from such expectations. If revenues are projected to change, the related amortization of the intangible assets will change in proportion to the change in revenues.

In connection with the Avadel Acquisition, the Company recorded the excess of the estimated fair value of the purchase price consideration over the fair value amounts assigned to the assets acquired and liabilities assumed as goodwill. For additional information related to the estimated purchase price consideration see Note 3, *Business Combination* in these "Notes to Condensed Consolidated Financial Statements". A rollforward of the Company's goodwill is as follows:

---

| | | |
|:---|:---|:---|
| **(In thousands)** | **Goodwill** | **Goodwill** |
| Goodwill at December 31, 2025 |  | 83,027 |
| &nbsp;&nbsp;&nbsp;Additions in connection with the Avadel Acquisition |  | 513,002 |
| Goodwill at March 31, 2026 |  | 596,029 |

---

------

**ALKERMES PLC AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Unaudited) (Continued)**

**10. LEASES**

Future lease payments under non-cancelable leases at March 31, 2026 consist of the following:

---

| | |
|:---|:---|
|  | **March 31,** |
| **(In thousands)** | **2026** |
| &nbsp;&nbsp;&nbsp;2026 | 8679 |
| &nbsp;&nbsp;&nbsp;2027 | 10713 |
| &nbsp;&nbsp;&nbsp;2028 | 10627 |
| &nbsp;&nbsp;&nbsp;2029 | 9827 |
| &nbsp;&nbsp;&nbsp;2030 | 9523 |
| &nbsp;&nbsp;&nbsp;Thereafter | 41025 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total operating lease payments | $90394 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Less: imputed interest | (19071) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total operating lease liabilities | $71323 |

---

At March 31, 2026, the weighted average incremental borrowing rate and the weighted average remaining lease term for all operating leases held by the Company were 3.6% and 5.6 years, respectively. Cash paid for lease liabilities was $2.8 million during the three months ended March 31, 2026, as compared to $2.5 million during the three months ended March 31, 2025. The Company recorded operating lease expense of $2.2 million during the three months ended March 31, 2026, as compared to $1.8 million during the three months ended March 31, 2025.

**11. ACCOUNTS PAYABLE AND ACCRUED EXPENSES**

Accounts payable and accrued expenses consist of the following:

---

| | | |
|:---|:---|:---|
|  | **March 31,** | **December 31,** |
| **(In thousands)** | **2026** | **2025** |
| Accounts payable | $102357 | $107950 |
| Accrued compensation | 53430 | 82450 |
| Accrued other | 136792 | 99165 |
| &nbsp;&nbsp;&nbsp;Total accounts payable and accrued expenses | $292579 | $289565 |

---

A summary of the Company's current provision for sales discounts, allowances and reserves was as follows:

---

| | | |
|:---|:---|:---|
|  | **March 31,** | **December 31,** |
| **(In thousands)** | **2026** | **2025** |
| Medicaid rebates | $189032 | $186068 |
| Product discounts | 18700 | 18688 |
| Medicare Part D | 25487 | 25372 |
| Other | 39624 | 16998 |
| &nbsp;&nbsp;&nbsp;Total accrued sales discounts, allowances and reserves | $272843 | $247126 |

---

Included in accounts payable was approximately $38.6 million and $59.6 million of amounts payable related to state U.S. Medicaid rebates as of March 31, 2026 and December 31, 2025, respectively.

**12. LONG-TERM DEBT**

Long-term debt consisted of the following:

---

| | | |
|:---|:---|:---|
|  | **March 31,** | **December 31,** |
| **(In thousands)** | **2026** | **2025** |
| Term Loan A Facility, due February 12, 2031 | $745098 | $— |
| Term Loan B Facility, due August 12, 2031 | 765239 |  |
| &nbsp;&nbsp;&nbsp;Less: current portion | (26500) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Long-term debt | $1483837 | $— |

---

------

**ALKERMES PLC AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Unaudited) (Continued)**

On the Closing Date, the Company entered into a credit agreement (the "Credit Agreement"), by and among Alkermes plc, as the TopCo Borrower, Alkermes, Inc., as the U.S. Borrower, Alkermes Finance LLC, as the U.S. Co-Borrower, JPMorgan Chase Bank, N.A., as Administrative Agent, Joint Lead Arranger and Joint Bookrunner, BofA Securities, Inc., as Joint Lead Arranger and Joint Bookrunner, and the lenders party thereto. The Credit Agreement provides for (i) a senior secured term loan A facility in an aggregate principal amount of up to $750.0 million (the "TLA Facility") and (ii) a senior secured term loan B facility in an aggregate principal amount of up to $775.0 million (the "TLB Facility" and together with the TLA Facility, the "Facilities"). The TLA Facility matures on February 12, 2031, and the TLB Facility matures on August 12, 2031. On the Closing Date, the Company borrowed the full $1.525 billion available under the Facilities.

Borrowings under the TLA Facility will bear interest at an annual rate of, at the Company's option, either (i) the Term SOFR Rate (as defined in the Credit Agreement) plus a Secured Net Leverage Ratio-(as defined in the Credit Agreement)-based margin, which will initially be 2.75% per annum or (ii) the Alternate Base Rate (as defined in the Credit Agreement) plus a Secured Net Leverage Ratio-based margin, which will initially be 1.75% per annum. Borrowings under the TLB Facility will bear interest at an annual rate of, at the Company's option, either (i) the Term SOFR Rate plus a margin of 2.75% per annum or (ii) the Alternate Base Rate plus a margin of 1.75% per annum. The Company has agreed to pay certain fees and expenses in connection with the Facilities, as set forth in the Credit Agreement and certain related fee letters.

The Credit Agreement (other than with respect to the TLB Facility) requires the maintenance of a maximum Secured Net Leverage Ratio and a minimum Consolidated Interest Coverage Ratio (as defined in the Credit Agreement), in each case, with the levels set forth in the Credit Agreement, as of the last day of any fiscal quarter of the Company ending after the Closing Date. In addition, the Credit Agreement contains customary affirmative and negative covenants that apply after the Closing Date, including limitations on indebtedness, liens, mergers, consolidations, sales of assets, investments, transactions with affiliates, restricted payments and sales and leasebacks. The Credit Agreement also contains certain customary events of default, including upon a change of control.

The Credit Agreement is guaranteed by subsidiary guarantors and secured by a lien on substantially all of the assets of the borrowers and the subsidiary guarantors, whether owned as of the Closing Date or thereafter acquired.

In November 2025, the Company entered into an amended and restated bridge term credit agreement, which provided for a senior secured bridge term loan facility in an aggregate amount of up to approximately $1.5 billion (the "Bridge Credit Facility") to fund a portion of the consideration for the Avadel Acquisition (the "Bridge Credit Agreement"). Loans under the Bridge Credit Facility were available, subject to the satisfaction of certain conditions set forth in the Bridge Credit Agreement, and were scheduled to mature on the date that is 364 days after the date on which the loans were funded under the Bridge Credit Facility. The commitments under the Bridge Credit Facility were to terminate on the earlier of (i) the date on which all of the consideration payable in respect of the Avadel Acquisition was paid in full without the making of any loans under the Bridge Credit Facility and (ii) the date on which a Mandatory Cancellation Event (as defined in the Bridge Credit Agreement) occurred or existed. Accordingly, on February 12, 2026, in connection with completion of the Avadel Acquisition and the Company's entry into the Credit Agreement, the Company terminated the Bridge Credit Agreement, as the commitments under the Credit Agreement, together with the Company's cash on hand, were sufficient to fund the Avadel Acquisition. During the three months ended March 31, 2026, the Company incurred approximately $7.7 million in financing costs related to the Bridge Credit Agreement which was recorded within "Interest expense" in the accompanying condensed consolidated statements of operations and comprehensive (loss) income.

Scheduled maturities with respect to the Facilities are as follows (in thousands):

---

| | |
|:---|:---|
| Year Ending December 31: |  |
| &nbsp;&nbsp;&nbsp;2026 | $19875 |
| &nbsp;&nbsp;&nbsp;2027 | 26500 |
| &nbsp;&nbsp;&nbsp;2028 | 40563 |
| &nbsp;&nbsp;&nbsp;2029 | 45250 |
| &nbsp;&nbsp;&nbsp;2030 | 45250 |
| Thereafter | 1347562 |
| Total | $1525000 |

---

------

**ALKERMES PLC AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Unaudited) (Continued)**

The Company is subject to mandatory prepayments of principal if certain excess cash flow thresholds, as defined in the Facilities, are met. To date, the Company has not been required to make any such mandatory prepayments. The Facilities also contain customary affirmative covenants and events of default. The Company was in compliance with its debt covenants at March 31, 2026.

At March 31, 2026, the Company's balance of unamortized deferred financing costs and unamortized original issue discount costs were $4.3 million and $12.0 million, respectively. These costs are being amortized to interest expense over the estimated repayment period of the Facilities using the effective interest method. During the three months ended March 31, 2026, the Company had amortization expense of $0.4 million related to deferred financing costs and original issue discount.

**13. SHAREHOLDERS' EQUITY**

In February 2024, the Company's board of directors approved a share repurchase program authorizing the Company to repurchase ordinary shares of the Company in an aggregate amount of up to $400.0 million (exclusive of any fees, commissions or other expenses related to such repurchases) from time to time on the open market (the "Repurchase Program"), with the specific timing and amounts of repurchases under the Repurchase Program dependent on a variety of factors, including but not limited to ongoing assessments of the Company's needs, alternative investment opportunities, the market price of the Company's ordinary shares and general market conditions. The Repurchase Program has no set expiration date and may be suspended or discontinued at any time. During the three months ended March 31, 2026, the Company repurchased approximately 1.0 million of its ordinary shares under the Repurchase Program at an average purchase price of $27.82 per share, resulting in a total cost, exclusive of any fees, commissions or other expenses related to such repurchases, of $27.7 million. All ordinary shares repurchased were returned to treasury. As of March 31, 2026, the remaining amount authorized under the Repurchase Program was $172.3 million.

**14. SHARE-BASED COMPENSATION**

The following table presents share-based compensation expense included in the accompanying condensed consolidated statements of operations and comprehensive (loss) income:

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| **(In thousands)** | **2026** | **2025** |
| Cost of goods manufactured and sold | $1753 | $1782 |
| Research and development | 8468 | 5891 |
| Selling, general and administrative | 26109 | 15137 |
| &nbsp;&nbsp;&nbsp;Share-based compensation expense | 36330 | 22810 |
| Research and development | 5940 |  |
| Selling, general and administrative | 12468 |  |
| &nbsp;&nbsp;&nbsp;Share-based compensation expense for acceleration of Avadel Shares | 18408 |  |
| Total share-based compensation expense | $54738 | $22810 |

---

At March 31, 2026 and December 31, 2025, $3.3 million and $3.2 million, respectively, of share-based compensation expense was capitalized and recorded as "Inventory", and $2.1 million and $1.6 million, respectively, of share-based compensation expense was capitalized and recorded as "Other assets" in the accompanying condensed consolidated balance sheets.

During the three months ended March 31, 2026, share-based compensation expense included: (i) $18.4 million in post-combination expense related to Avadel Shares that were accelerated and settled by the Company on the Closing Date in connection with the Avadel Acquisition; (ii) $1.8 million in post-combination expense related to the contingent liability related to the potential CVR payment to former Avadel employees and (iii) $4.9 million in expense related to certain equity awards that were modified by the letter agreement entered into in February 2026 between the Company and Richard Pops (the "Letter Agreement") in connection with Mr. Pops' upcoming retirement from his position as the Company's Chief Executive Officer. The share-based compensation expense related to these events consisted of $18.5 million in selling, general and administrative expense and $6.6 million in R&D expense.

The Company expects to record an additional $1.1 million in incremental share-based compensation expense through May 2027 in connection with the equity modification resulting from the Letter Agreement.

------

**ALKERMES PLC AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Unaudited) (Continued)**

**15. (LOSS) EARNINGS PER ORDINARY SHARE**

Basic (loss) earnings per ordinary share is calculated based upon net (loss) income available to holders of ordinary shares, divided by the weighted average number of ordinary shares outstanding. For the calculation of diluted (loss) earnings per ordinary share, the Company utilizes the treasury stock method and adjusts the weighted average number of ordinary shares outstanding for the potential dilutive effect of outstanding ordinary share equivalents such as stock options and restricted stock unit awards.

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| **(In thousands)** | **2026** | **2025** |
| Numerator: |  |  |
| &nbsp;&nbsp;&nbsp;Net (loss) income | $(66480) | $22464 |
| Denominator: |  |  |
| Weighted average number of ordinary shares outstanding | 166196 | 163407 |
| Effect of dilutive securities: |  |  |
| &nbsp;&nbsp;&nbsp;Stock options |  | 2393 |
| &nbsp;&nbsp;&nbsp;Restricted stock unit awards |  | 2937 |
| &nbsp;&nbsp;&nbsp;&nbsp;Dilutive ordinary share equivalents |  | 5330 |
| Shares used in calculating diluted (loss) earnings per ordinary share | 166196 | 168737 |

---

The following potential ordinary share equivalents were not included in the net (loss) earnings per ordinary share calculation because the effect would have been anti-dilutive:

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** |
|  | **March 31,** | **March 31,** |
| **(In thousands)** | **2026** | **2025** |
| Stock options | 9348 | 6141 |
| Restricted stock unit awards | 4199 | 1818 |
| &nbsp;&nbsp;&nbsp;Total | 13547 | 7959 |

---

**16. INCOME TAXES**

The Company recognizes income taxes under the asset and liability method. Deferred income taxes are recognized for differences between the financial reporting and tax bases of assets and liabilities at enacted statutory tax rates in effect for the years in which the differences are expected to reverse. The effect on deferred taxes of a change in tax rates is recognized in income in the period that includes the enactment date. In determining future taxable income, the Company is responsible for assumptions that it utilizes, including the amount of Irish and non-Irish pre-tax operating income, the reversal of temporary differences and the implementation of feasible and prudent tax planning strategies. These assumptions require significant judgment about the forecasts of future taxable income and are consistent with the plans and estimates that the Company uses to manage the underlying business.

As of March 31, 2026, the Company has recognized $134.8 million of deferred tax assets and, based on all available evidence related to the likelihood of realization of the existing and acquired tax attributes and the weight of the available evidence, believes it is more-likely-than-not that the deferred tax assets of $134.8 million will be realized. For a discussion about the deferred tax assets and liabilities acquired in connection with the Avadel Acquisition, see Note 3, *Business Combination* in these "Notes to Condensed Consolidated Financial Statements".

The Company recorded income tax provisions of $4.6 million and $3.0 million during the three months ended March 31, 2026 and 2025, respectively. The income tax provision during the three months ended March 31, 2026 was primarily attributable to taxes on income earned in the U.S. and the income tax provision during the three months ended March 31, 2025 was primarily attributable to taxes on income earned in Ireland.

The Company's effective tax rate during the three months ended March 31, 2026 and 2025 was (7.4)% and 11.9%, respectively. The negative effective tax rate during the three months ended March 31, 2026 was due to taxes on income (including non-deductible expenses) earned in the U.S. and an overall loss before income taxes The effective tax rate during the three months ended March 31, 2025 was less than the Irish statutory rate of 12.5%, due primarily to windfall benefits from employee equity activity.

------

**ALKERMES PLC AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Unaudited) (Continued)**

In March 2026, the Company was notified by the U.S. Internal Revenue Service that Alkermes US Holdings, Inc. ("Alkermes US Holdings"), a wholly-owned subsidiary of the Company, and subsidiaries of Alkermes US Holdings have been selected for examination for the year ended December 31, 2023.

**17. SEGMENT REPORTING**

***Segment Information***

The Company's significant segment expenses that are regularly provided to the Company's CODM are as follows:

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** |
|  | **March 31,** | **March 31,** |
| **(In thousands)** | **2026** | **2025** |
| REVENUES: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total revenue | $392911 | $306510 |
| EXPENSES: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cost of goods manufactured and sold (exclusive of amortization of acquired intangible assets shown below) | 61578 | 49197 |
| &nbsp;&nbsp;&nbsp;&nbsp;External R&D expenses: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Development programs: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Alixorexton | 25497 | 17854 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;LYBALVI | 4449 | 3852 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;LUMRYZ | 2923 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other external R&D expenses | 17960 | 10973 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total external R&D expenses | 50829 | 32679 |
| &nbsp;&nbsp;&nbsp;&nbsp;Internal R&D expenses: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Employee-related | 43615 | 31354 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Occupancy | 3264 | 3148 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation | 1688 | 1467 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other internal R&D expenses | 3949 | 3169 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total internal R&D expenses | 52516 | 39138 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;R&D expenses | 103345 | 71817 |
| &nbsp;&nbsp;&nbsp;&nbsp;Selling, general and administrative expenses: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Selling and marketing expense | 155563 | 122934 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General and administrative expense | 109030 | 48770 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total selling, general and administrative expense | 264593 | 171704 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other segment (expense) income <sup>(1)</sup> | (29875) | 8672 |
| NET INCOME | (66480) | 22464 |

---

------

&nbsp;&nbsp;&nbsp;&nbsp;(1)"Other segment (expense) income" during the three months ended March 31, 2026 and 2025, includes "Amortization of acquired intangible assets", "Other (expense) income, net" and "Income tax provision".

**18. COMMITMENTS AND CONTINGENT LIABILITIES**

*Contingent Consideration*

The Company records contingent consideration it may owe related to a business combination at fair value on the acquisition date. The fair value of the contingent consideration is estimated through valuation models that incorporate a probability-weighted discounted cash flow model related to the achievement of a certain specified milestone. The contingent consideration is revalued at each subsequent reporting period, with changes in the fair value of contingent consideration recognized within the consolidated statements of operations and comprehensive (loss) income. Changes in the fair value of contingent consideration can result from changes to one or multiple assumptions, including adjustments to the discount rates, changes in the assumed achievement and timing of such specified milestone and changes in the assumed probability associated with regulatory approval.

------

**ALKERMES PLC AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Unaudited) (Continued)**

The period over which the Company discounts its contingent consideration is based on the current development stage of the product candidate, the specific development plan for that product candidate adjusted for the probability of completing the development step, and the date on which contingent payments may be triggered. In estimating the probability of success, the Company utilizes data regarding similar milestone events from several sources, including industry studies and its own experience. These fair value measurements are based on significant inputs not observable in the market. Significant judgment is employed in determining the appropriateness of these assumptions at the acquisition date and for each subsequent reporting period. Accordingly, changes in assumptions described above could have a material impact on the increase or decrease in the fair value of contingent consideration recorded in any given period.

At March 31, 2026, the Company recorded a contingent consideration related to the CVR Milestone issued in connection with the Avadel Acquisition. For additional information related to the contingent consideration, see Note 3, *Business Combination* in these "Notes to Condensed Consolidated Financial Statements".

The fair value of the contingent consideration was determined as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•As part of consideration for the Avadel Acquisition, holders of Avadel Shares as of the Closing Date are entitled to receive a potential additional aggregate cash payment of $165.7 million, or $1.50 per Avadel Share, upon achievement of the CVR Milestone; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•The fair value of the contingent consideration was estimated by applying a discount factor, calculated based on the likelihood of achievement of the CVR Milestone, from the expected time the milestone occurs to the end of the reporting period, to the estimated probability of success. The Company expects the regulatory milestone event to occur no later than the end of 2028 and used a discount rate of 5.47%.

Significant judgment was employed in determining the appropriateness of these assumptions at the acquisition date. Accordingly, changes in assumptions described above could have a material impact on the increase or decrease in the fair value of contingent consideration we record in any given period. In accordance with the accounting standard for fair value measurements, the fair value of the contingent consideration has been classified as a Level 3 liability as its fair value is based on significant inputs not observable in the market. For additional information related to the fair value classification of the contingent consideration, see Note 6, *Fair Value* in these "Notes to Condensed Consolidated Financial Statements".

*Litigation*

From time to time, the Company may be subject to legal proceedings and claims in the ordinary course of business. On a quarterly basis, the Company reviews the status of each significant matter and assesses its potential financial exposure. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated, the Company would accrue a liability for the estimated loss. Because of uncertainties related to claims and litigation, accruals are based on the Company's best estimates, utilizing all available information. On a periodic basis, as additional information becomes available, or based on specific events such as the outcome of litigation or settlement of claims, the Company may reassess the potential liability related to these matters and may revise these estimates, which could result in material adverse adjustments to the Company's operating results. At March 31, 2026, there were no potential material losses from claims, asserted or unasserted, or legal proceedings that the Company determined were probable of occurring. For claims that are reasonably possible, no estimable loss or range of loss can be made.

**<u>LYBALVI ANDA Litigation</u>**

In August 2025, Alkermes Pharma Ireland Limited ("APIL") and Alkermes, Inc., two wholly-owned subsidiaries of the Company, filed a patent infringement lawsuit against Teva (as defined herein) in the NJ District Court and a patent infringement lawsuit against Apotex in each of the NJ District Court and the U.S. District Court for the District of Delaware. In September 2025, APIL and Alkermes, Inc. filed a patent infringement lawsuit against MSN (as defined herein) in the NJ District Court. As used herein, Teva refers to Teva Pharmaceuticals, Inc., Apotex refers to Apotex Inc. and Apotex Corp., and MSN refers to MSN Laboratories Private Limited ("MSN Labs"), MSN Pharmaceuticals, Inc. and Novadoz Pharmaceuticals LLC. These lawsuits were filed following receipt of a "paragraph IV certification" notice from each of Teva, Apotex and MSN Labs regarding their respective filings of an ANDA with the FDA seeking approval to engage in the commercial manufacture, use or sale of a generic version of LYBALVI (olanzapine and samidorphan tablets, 5mg/10mg, 10mg/10mg, 15mg/10mg and 20mg/10mg) in the U.S. prior to the expiration of certain of the Company's U.S. patents. The notices alleged that certain of the Company's patents related to LYBALVI are

------

**ALKERMES PLC AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Unaudited) (Continued)**

invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of the proposed generic products. The Company intends to vigorously defend its intellectual property. The filing of each lawsuit within 45 days of receipt of each of the respective notices triggered stays of FDA approval of each of the respective ANDAs for up to 30 months in accordance with the U.S. Drug Price Competition and Patent Term Restoration Act of 1984 (the "Hatch-Waxman Act").

**<u>Antitrust Class Action Litigation</u>**

In October 2025, Value Drug Company filed a complaint asserting antitrust claims against Alkermes, Inc. and APIL in the U.S. District Court for the District of Massachusetts (the "MA District Court"). The complaint was filed on behalf of a putative class of direct purchasers of VIVITROL and alleges that the Company's U.S. Patent No. 7,919,499 related to VIVITROL was fraudulently obtained, improperly listed in the Orange Book, and wrongfully enforced, resulting in delayed market entry for generic forms of VIVITROL. The lawsuit seeks, among other things, unspecified money damages plus interest, reasonable attorneys' fees and other costs. The Company intends to vigorously defend itself in this matter. In December 2025, Alkermes, Inc. and APIL filed a motion to dismiss the complaint with the MA District Court.

**<u>Government Matters</u>**

The Company has received a civil investigative demand from a U.S. state governmental authority. The Company is cooperating with the investigation.

**<u>Other Legal Proceedings</u>**

The Company is involved in litigation and other legal proceedings incidental to its normal business activities. The Company intends to vigorously defend itself in these matters.

In addition, in January 2023, Acorda Therapeutics, Inc. ("Acorda") filed a petition with the U.S. District Court for the Southern District of New York (the "NY Southern District Court") asking the court to confirm in part and modify in part the final arbitral award rendered by an arbitration panel in October 2022 and, as part of the requested modification, seeking an additional approximately $66.0 million in damages. In August 2023, the NY Southern District Court confirmed the final arbitral award and declined to modify the final award to increase the damages awarded thereunder. In September 2023, Acorda filed a notice of appeal of the NY Southern District Court decision to the Federal Circuit Court. In July 2025, the Federal Circuit Court transferred the appeal due to lack of jurisdiction to the U.S. Court of Appeals for the Second Circuit (the "Second Circuit"). Oral arguments in the Second Circuit are scheduled to be held on May 20, 2026.

------

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations**

The following discussion should be read in conjunction with the accompanying condensed consolidated financial statements and related notes beginning on page 5 in this Form 10-Q, and "Part II, Item 7—Management's Discussion and Analysis of Financial Condition and Results of Operations" and the audited financial statements and notes thereto accompanying our Annual Report.

**Executive Summary**

Net loss was $66.5 million or $0.40 per ordinary share—basic and diluted, for the three months ended March 31, 2026, compared to net income of $22.5 million or $0.14 per ordinary share—basic and $0.13 per ordinary share—diluted, for the three months ended March 31, 2025.

The change in net loss of $88.9 million was primarily due to an increase of $148.5 million in total operating expenses, due to increases in cost of goods manufactured and sold, R&D expenses, selling, general and administrative expenses and amortization of acquired intangible assets, and due to an increase of $20.9 million of interest expense. These increases were primarily related to expenses incurred in connection with the Avadel Acquisition. Total revenues increased by $86.4 million, primarily due to an increase in product sales, net, partially offset by a decrease in manufacturing and royalty revenue.

These items are discussed in greater detail later in the "Results of Operations" section in this "Part I, Item 2—Management's Discussion and Analysis of Financial Condition and Results of Operations" in this Form 10-Q.

**Business Update**

On February 12, 2026, we completed the Avadel Acquisition, adding LUMRYZ to our portfolio of proprietary commercial products and a commercial organization with experience in narcolepsy. Pursuant to the Transaction Agreement, we acquired the entire issued and to be issued ordinary share capital of Avadel for consideration of (i) $21.00 per Avadel Share, payable in cash at closing and (ii) a non-transferable CVR entitling holders of Avadel Shares to a potential additional cash payment of $1.50 per Avadel Share, contingent upon achievement of a certain specified milestone. During the three months ended March 31, 2026, we incurred costs of approximately $34.8 million in connection with the Avadel Acquisition.

**Products**

<u>Marketed Products</u>

The key marketed products discussed below have generated, or are expected to generate, significant revenues for us. See the descriptions of the marketed products below and "Part I, Item 1A—Risk Factors" in our Annual Report for important factors that could adversely affect our marketed products. See the "Patents and Proprietary Rights" section in "Part I, Item 1—Business" in our Annual Report for information with respect to the IP protection for these marketed products.

------

The following provides summary information regarding our proprietary products that we commercialize:

***Proprietary Products*** 

---

| | | |
|:---|:---|:---|
| **Product** | **Indicated Disease State** | **Territory** |
| ![img42436816_1.jpg](img42436816_1.jpg) | Schizophrenia (Initiation or re-initiation of ARISTADA)  | U.S. |
| ![img42436816_1.jpg](img42436816_1.jpg) | Schizophrenia | U.S. |
| ![img42436816_2.gif](img42436816_2.gif) | Narcolepsy | U.S. |
| ![img42436816_3.gif](img42436816_3.gif) | Schizophrenia;<br>Bipolar I disorder <br>| U.S. |
| ![img42436816_4.gif](img42436816_4.gif) | Alcohol dependence;<br>Opioid dependence | U.S. |

---

------

The following provides summary information regarding certain key third-party products using our proprietary technologies under license and our key licensed product, that are commercialized by our licensees:

***Key Third-Party Products Using Our Proprietary Technologies***

---

| | | | |
|:---|:---|:---|:---|
| **Product** | **Indicated Disease State** | **Licensee** | **Licensed Territory** |
| &nbsp;&nbsp;&nbsp;***INVEGA SUSTENNA / XEPLION*** | *INVEGA SUSTENNA*:<br>Schizophrenia; Schizoaffective <br>disorder<br>*XEPLION*:<br>Schizophrenia | Janssen Pharmaceutica <br>(together with Janssen Pharmaceuticals, Inc., Janssen International and their affiliates "Janssen") | Worldwide |
| &nbsp;&nbsp;&nbsp;***INVEGA TRINZA / TREVICTA*** | Schizophrenia | Janssen | Worldwide |
| &nbsp;&nbsp;&nbsp;***INVEGA HAFYERA / BYANNLI*** | Schizophrenia | Janssen | Worldwide |

---

***Our Key Licensed Product***

---

| | | | |
|:---|:---|:---|:---|
| **Product** | **Indicated Disease State** | **Licensee** | **Licensed Territory** |
| &nbsp;&nbsp;&nbsp;***VUMERITY*** | Multiple sclerosis | Biogen | Worldwide |

---

*Proprietary Products*

We have developed and now commercialize products designed to help address the unmet needs of people living with opioid dependence, alcohol dependence, schizophrenia, bipolar I disorder and narcolepsy. See the "Patents and Proprietary Rights" section in "Part I, Item 1—Business" in our Annual Report for information with respect to the IP protection for our proprietary products.

***ARISTADA and ARISTADA INITIO***

ARISTADA (aripiprazole lauroxil) is an extended-release intramuscular injectable suspension approved in the U.S. for the treatment of schizophrenia. ARISTADA utilizes our proprietary LINKERX technology. ARISTADA is a prodrug; once in the body, ARISTADA is likely converted by enzyme-mediated hydrolysis to N-hydroxymethyl aripiprazole, which is then hydrolyzed to aripiprazole. ARISTADA is available in four dose strengths with once-monthly dosing options (441 mg, 662 mg and 882 mg), a six-week dosing option (882 mg) and a two-month dosing option (1064 mg). ARISTADA is packaged in a ready-to-use, pre-filled syringe product format. We exclusively manufacture and commercialize ARISTADA in the U.S.

ARISTADA INITIO (aripiprazole lauroxil) leverages our proprietary LINKERX and NANOCRYSTAL technologies and provides an extended-release formulation of aripiprazole lauroxil in a smaller particle size compared to ARISTADA, thereby enabling faster dissolution and more rapid achievement of relevant levels of aripiprazole in the body. ARISTADA INITIO, combined with a single 30 mg dose of oral aripiprazole, is indicated for the initiation of ARISTADA when used for the treatment of schizophrenia in adults. The first ARISTADA dose may be administered on the same day as the ARISTADA INITIO regimen or up to 10 days thereafter. We exclusively manufacture and commercialize ARISTADA INITIO in the U.S.

------

***LUMRYZ***

LUMRYZ (sodium oxybate) is an extended-release oral suspension product approved by the U.S. Food and Drug Administration ("FDA") in May 2023 and October 2024 as the first and only once-at-bedtime treatment for cataplexy or excessive daytime sleepiness ("EDS") in adults with narcolepsy and in pediatric patients seven years of age and older with narcolepsy, respectively. The FDA has granted seven years of orphan drug exclusivity ("ODE") to LUMRYZ for the adult and pediatric narcolepsy patient populations through May 1, 2030 and October 16, 2031, respectively. We exclusively commercialize LUMRYZ in the U.S. Pursuant to the settlement and license agreement entered into between Jazz Pharmaceuticals entities and Avadel entities in October 2025 (the "Avadel Settlement Agreement"), from October 1, 2025, Jazz receives a royalty of 3.85% (subject to certain adjustments set forth in the Avadel Settlement Agreement) on net sales of LUMRYZ sold for narcolepsy and additional royalties on net sales of LUMRYZ sold for any other non-narcolepsy indications. For more information about the Avadel Settlement Agreement and underlying royalty obligations, see "Patents and Proprietary Rights – LUMRYZ" in "Item 1—Business" in our Annual Report.

LUMRYZ employs a version of our MICROPUMP technology. LUMRYZ is manufactured by third parties. The FDA has required implementation of a risk evaluation and mitigation strategy ("REMS") for LUMRYZ to help ensure the benefits of the drug outweigh any risks of serious adverse outcomes that may result from inappropriate prescribing, misuse, abuse or diversion of the product. Under the LUMRYZ REMS, healthcare providers who prescribe the drug must be specially certified, pharmacies that dispense the drug must be specially certified, and the drug must be dispensed only to patients who have enrolled in the LUMRYZ REMS and completed all REMS requirements, including documentation of safe use conditions.

***LYBALVI*** 

LYBALVI (olanzapine and samidorphan) is a once-daily, oral atypical antipsychotic drug approved in the U.S. for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. LYBALVI is a combination of olanzapine, an atypical antipsychotic, and samidorphan, an opioid antagonist, in a single bilayer tablet. LYBALVI is available in fixed dosage strengths composed of 10 mg of samidorphan and 5 mg, 10 mg, 15 mg or 20 mg of olanzapine. We exclusively manufacture and commercialize LYBALVI in the U.S.

For a discussion of legal proceedings related to LYBALVI, see Note 18, *Commitments and Contingent Liabilities* in the "Notes to Condensed Consolidated Financial Statements" in this Form 10-Q, and for information about risks relating to such legal proceedings, see "Part I, Item 1A—Risk Factors" in our Annual Report and specifically the section entitled "Uncertainty over IP in the biopharmaceutical industry has been the source of litigation and other legal proceedings, and we and our licensees have previously and may in the future face claims against IP rights covering our products and competition from generic drug manufacturers."

***VIVITROL***

VIVITROL (naltrexone for extended-release injectable suspension) is a once-monthly, non-narcotic, injectable medication approved in the U.S. for the treatment of alcohol dependence in patients able to abstain from alcohol in an outpatient setting prior to initiation of treatment with VIVITROL and for the prevention of relapse to opioid dependence, following opioid detoxification. VIVITROL uses our polymer-based microsphere injectable extended-release technology to deliver and maintain therapeutic medication levels in the body through one intramuscular injection every four weeks. We exclusively manufacture and commercialize VIVITROL in the U.S.

For a discussion of legal proceedings related to VIVITROL, see Note 18, *Commitments and Contingent Liabilities* in the "Notes to Condensed Consolidated Financial Statements" in this Form 10-Q, and for information about risks relating to such legal proceedings, see "Part I, Item 1A—Risk Factors" in our Annual Report and specifically the sections entitled "Uncertainty over IP in the biopharmaceutical industry has been the source of litigation and other legal proceedings, and we and our licensees have previously and may in the future face claims against IP rights covering our products and competition from generic drug manufacturers" and "Litigation or arbitration filed against Alkermes, including securities litigation, or actions (such as citizens petitions) filed against regulatory agencies in respect of our products, may result in financial losses, harm our reputation, divert management resources, negatively impact the approval of our products, or otherwise negatively impact our business."

------

*Products Using Our Proprietary Technologies and Licensed Product*

We have licensed products to third parties for commercialization and have licensed our proprietary technologies to third parties to enable them to develop, commercialize and/or manufacture products. See the "Proprietary Technology Platforms" and "Patents and Proprietary Rights" sections in "Part I, Item 1—Business" in our Annual Report for information with respect to our proprietary technologies and the IP protection for these products. We receive royalties and/or manufacturing and other revenues from the commercialization of these products under our collaborative arrangements with these third parties. Such arrangements, among others, include the following:

*Products Using Our Proprietary Technologies* 

***INVEGA SUSTENNA/XEPLION, INVEGA TRINZA/TREVICTA and INVEGA HAFYERA/BYANNLI*** 

The long-acting INVEGA products are long-acting atypical antipsychotics owned and commercialized worldwide by Janssen. We believe that these products incorporate our technologies.

INVEGA SUSTENNA is approved in the U.S. for the treatment of schizophrenia and for the treatment of schizoaffective disorder as either a monotherapy or adjunctive therapy. Paliperidone palmitate extended-release injectable suspension is approved in the European Union ("EU") and other countries outside of the U.S. for the treatment of schizophrenia and is marketed and sold under the trade name XEPLION. INVEGA SUSTENNA/XEPLION is manufactured by Janssen.

INVEGA TRINZA is approved in the U.S. for the treatment of schizophrenia in patients who have been adequately treated with INVEGA SUSTENNA for at least four months. TREVICTA is approved in the EU for the maintenance treatment of schizophrenia in adult patients who are clinically stable on XEPLION. INVEGA TRINZA/TREVICTA is manufactured by Janssen.

INVEGA HAFYERA is approved in the U.S. for the treatment of schizophrenia in patients who have been adequately treated with INVEGA SUSTENNA for at least four months or INVEGA TRINZA for at least three months. BYANNLI is approved in the EU for the maintenance treatment of schizophrenia in adult patients who are clinically stable on XEPLION or TREVICTA. INVEGA HAFYERA/BYANNLI is manufactured by Janssen.

*Licensed Product*

***VUMERITY*** 

VUMERITY (diroximel fumarate) is a novel, oral fumarate with a distinct chemical structure that is approved in the U.S., the EU and several other countries for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.

Under our license and collaboration agreement with Biogen, Biogen holds the exclusive, worldwide license to develop and commercialize VUMERITY. For more information about the license and collaboration agreement with Biogen, see the "Collaborative Arrangements—Biogen" section in "Part I, Item 1—Business" in our Annual Report.

<u>Key Development Programs</u>

Our R&D is focused on the development of innovative medicines in the field of neuroscience that are designed to address unmet patient needs. As part of our ongoing R&D efforts, we have devoted, and will continue to devote, significant resources to conducting preclinical work and clinical studies to advance the development of new pharmaceutical products. The discussion below highlights our current key development programs. Drug development involves a high degree of risk and investment, and the status, timing and scope of our development programs are subject to change. Important factors that could adversely affect our drug development efforts are discussed in "Part I, Item 1A—Risk Factors" in our Annual Report. See the "Patents and Proprietary Rights" section in "Part I, Item 1—Business" in our Annual Report for information with respect to the IP protection for our key development programs.

------

***Alixorexton*** 

Alixorexton is a novel, investigational, oral, selective orexin 2 receptor agonist in development for the treatment of narcolepsy type 1 ("NT1"), narcolepsy type 2 ("NT2") and idiopathic hypersomnia ("IH"). Orexin, a neuropeptide produced in the lateral hypothalamus, is considered to be the master regulator of wakefulness due to its activation of multiple, downstream wake-promoting pathways that project widely throughout the brain. Targeting the orexin system may address excessive daytime sleepiness across hypersomnolence disorders, whether or not deficient orexin signaling is the underlying cause of disease. Once-daily oral administration of alixorexton was previously evaluated in a phase 1 study in healthy volunteers and patients with NT1, NT2 and IH and in Vibrance-1 and Vibrance-2, phase 2 studies in patients with NT1 and NT2, respectively. In April 2026, we announced the initiation of the Brilliance Studies, a phase 3 program evaluating the safety and efficacy of alixorexton compared to placebo in adults with NT1 and NT2. Alixorexton is also currently being evaluated in Vibrance-3, a phase 2 study in patients with IH. Alixorexton has received Breakthrough Therapy designation from the FDA for the treatment of NT1.

***LUMRYZ (sodium oxybate)*** 

LUMRYZ (sodium oxybate) extended-release oral suspension is currently being evaluated in REVITALYZ, a double-blind, placebo-controlled, randomized withdrawal, multicenter phase 3 study designed to evaluate efficacy and safety in adult patients with IH. Patient enrollment in this study was completed in December 2025.

**Results of Operations**

*Product Sales, Net*

Our product sales, net, consist of sales of ARISTADA and ARISTADA INITIO, LYBALVI, VIVITROL, and, following the completion of the Avadel Acquisition on February 12, 2026, LUMRYZ, primarily to wholesalers, specialty distributors and specialty pharmacies. The following table presents the adjustments deducted from product sales, gross to arrive at product sales, net, for sales of ARISTADA and ARISTADA INITIO, LUMRYZ, LYBALVI and VIVITROL during the three months ended March 31, 2026 and 2025:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** |
|  | **March 31,** | **March 31,** | **March 31,** | **March 31,** |
| **(In millions, except for % of Sales)** | **2026**<sup>(1)</sup> | **% of Sales**<sup>(1)</sup> | **2025** | **% of Sales** |
| Product sales, gross | $626.6 | 100.0% | $472.8 | 100.0% |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjustments to product sales, gross: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Medicaid rebates | (115.1) | (18.4)% | (94.3) | (19.9)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chargebacks | (60.7) | (9.7)% | (53.9) | (11.4)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Product discounts | (45.2) | (7.2)% | (37.3) | (7.9)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Medicare Part D | (19.9) | (3.2)% | (17.7) | (3.8)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other | (47.6) | (7.5)% | (25.1) | (5.3)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total adjustments | (288.5) | (46.0)% | (228.3) | (48.3)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Product sales, net | $338.1 | 54.0% | $244.5 | 51.7% |

---

------

&nbsp;&nbsp;&nbsp;&nbsp;(1)"Product sales, net" during the three months ended March 31, 2026 includes LUMRYZ beginning on February 12, 2026. Product sales, net amounts related to LUMRYZ are included within "Product sales, gross", "Product discounts", "Medicare Part D" and "Other".

The increase in product sales, gross was due to the addition of LUMRYZ, and increases of 29%, 15% and 5% in the number of units sold for LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, respectively, and a 6% price increase for each of LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL that went into effect on January 1, 2026.

The decrease in Medicaid rebates as a percentage of sales was primarily due to gross-to-net favorability, as actual Medicaid rebates related to VIVITROL, ARISTADA/ARISTADA INITIO and LYBALVI were lower than original estimates by approximately $5.4 million, $2.8 million and $0.5 million, respectively, and due to the inclusion of sales of LUMRYZ, which does not participate in a Medicaid rebate program. The increase in Other adjustments is related to the addition of certain gross-to-net deductions related to LUMRYZ.

------

The following table compares product sales, net earned during the three months ended March 31, 2026 and 2025:

---

| | | | |
|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** |  |
|  | **March 31,** | **March 31,** |  |
| **(In millions)** | **2026** | **2025** | **Change** |
| &nbsp;&nbsp;&nbsp;VIVITROL | $112.4 | $101.0 | $11.4 |
| &nbsp;&nbsp;&nbsp;ARISTADA and ARISTADA INITIO | 93.8 | 73.5 | 20.3 |
| &nbsp;&nbsp;&nbsp;LYBALVI | 92.4 | 70.0 | 22.4 |
| &nbsp;&nbsp;&nbsp;LUMRYZ | 39.5 |  | 39.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;Product sales, net | $338.1 | $244.5 | $93.6 |

---

*Manufacturing and Royalty Revenues*

The following table compares manufacturing and royalty revenues earned during the three months ended March 31, 2026 and 2025:

---

| | | | |
|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** |  |
|  | **March 31,** | **March 31,** |  |
| **(In millions)** | **2026** | **2025** | **Change** |
| Manufacturing and royalty revenues: |  |  |  |
| &nbsp;&nbsp;&nbsp;Long-acting INVEGA products | $18.0 | $17.7 | $0.3 |
| &nbsp;&nbsp;&nbsp;VUMERITY | 27.3 | 27.8 | (0.5) |
| &nbsp;&nbsp;&nbsp;Other | 9.5 | 16.5 | (7.0) |
| &nbsp;&nbsp;&nbsp;&nbsp;Manufacturing and royalty revenues | $54.8 | $62.0 | $(7.2) |

---

The decrease in VUMERITY revenue was due to a decrease of $6.0 million in manufacturing revenue, offset by an increase of $5.5 million in royalty revenue. The decrease in VUMERITY manufacturing revenue was related to the conclusion of our VUMERITY manufacturing subcontracting obligations for Biogen in August 2025. The increase in VUMERITY royalty revenue was due to an increase in end-market net sales of the product.

The decrease in Other manufacturing and royalty revenue was due to a $5.0 million decrease in RISPERDAL CONSTA manufacturing revenue, primarily due to a decrease in the number of batches made available to Janssen for sale in the U.S., which has a higher selling price than product sold outside of the U.S. and due to a decrease in revenues related to certain of our other legacy products.

**Costs and Expenses**

*Cost of Goods Manufactured and Sold*

---

| | | | |
|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** |  |
|  | **March 31,** | **March 31,** |  |
| **(In millions)** | **2026** | **2025** | **Change** |
| Cost of goods manufactured and sold | $61.6 | $49.2 | $12.4 |

---

In connection with the Avadel Acquisition, we acquired LUMRYZ inventory at its estimated fair value, resulting in a step-up of approximately $121.6 million above its cost. The inventory step-up is recognized in cost of goods manufactured and sold as the underlying inventory is sold. See Note 7, *Inventory* in the "Notes to Condensed Consolidated Financial Statements" in this Form 10-Q for additional information related to purchase accounting adjustments. The increase in the cost of goods manufactured and sold was primarily related to the addition of LUMRYZ and the amortization of such inventory step-up of approximately $12.7 million, and to the cost of goods sold for ARISTADA/ARISTADA INITIO, LYBALVI and VIVITROL due to increases in the number of units sold, as discussed above. These increases were partially offset by a decrease of $8.9 million in the cost of goods manufactured for certain legacy products following the completion of our subcontracting arrangements for the manufacture of such products by the end of 2025.

------

*Research and Development Expenses*

For each of our R&D programs, we incur both external and internal expenses. External R&D expenses include fees for clinical and preclinical activities performed by contract research organizations, consulting fees, and costs related to laboratory services, the purchase of drug product materials and third-party manufacturing development activities. Internal R&D expenses include employee-related expenses, occupancy costs, depreciation and general overhead. We track external R&D expenses for each of our development programs; however, internal R&D expenses are not tracked by individual program as they can benefit multiple development programs or our products or technologies in general.

The following table sets forth our external R&D expenses for the three months ended March 31, 2026 and 2025 relating to our then-current development programs and our internal R&D expenses, listed by the nature of such expenses:

---

| | | | |
|:---|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** |  |
| **(In millions)** | **2026** | **2025** | **Change** |
| External R&D expenses: |  |  |  |
| &nbsp;&nbsp;&nbsp;Development programs: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Alixorexton | $25.5 | $17.8 | $7.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;LYBALVI | 4.4 | 3.9 | 0.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;LUMRYZ | 2.9 |  | 2.9 |
| &nbsp;&nbsp;&nbsp;Other external R&D expenses | 18.0 | 11.0 | 7.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total external R&D expenses | 50.8 | 32.7 | 18.1 |
| Internal R&D expenses: |  |  |  |
| &nbsp;&nbsp;&nbsp;Employee-related | 43.6 | 31.4 | 12.2 |
| &nbsp;&nbsp;&nbsp;Occupancy | 3.3 | 3.1 | 0.2 |
| &nbsp;&nbsp;&nbsp;Depreciation | 1.7 | 1.4 | 0.3 |
| &nbsp;&nbsp;&nbsp;Other | 3.9 | 3.2 | 0.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total internal R&D expenses | 52.5 | 39.1 | 13.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and development expenses | $103.3 | $71.8 | $31.5 |

---

These amounts are not necessarily predictive of future R&D expenses. In an effort to allocate our spending most effectively, we continually evaluate our products under development based on the performance of such products in preclinical and/or clinical trials, our expectations regarding the likelihood of their regulatory approval and our view of their future potential commercial viability, among other factors.

The increase in expenses related to alixorexton was primarily due to increased spend related to the advancement of the development program, including initiation of our phase 3 Brilliance Studies of the product in narcolepsy and costs related to our long-term extension study. The increase in expenses related to LUMRYZ was due to the addition of the REVITALYZ program in connection with the Avadel Acquisition. The increase in other external R&D expenses was primarily due to activities associated with our preclinical and clinical development programs.

The increase in employee-related expenses was primarily due to an increase in share-based compensation expense of approximately $6.5 million related to Avadel Shares that were accelerated and settled by us in connection with the Avadel Acquisition and due to increases in labor and benefits expense related to a 20% increase in R&D-related headcount, primarily in connection with the Avadel Acquisition. See Note 3, *Business Combination* in the "Notes to Condensed Consolidated Financial Statements" in this Form 10-Q for additional information related to purchase accounting adjustments.

*Selling, General and Administrative Expense*

---

| | | | |
|:---|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** |  |
| **(In millions)** | **2026** | **2025** | **Change** |
| Selling and marketing expense | $155.6 | $122.9 | $32.7 |
| General and administrative expense | 109.0 | 48.8 | 60.2 |
| &nbsp;&nbsp;&nbsp;Selling, general and administrative expense | $264.6 | $171.7 | $92.9 |

---

The increase in selling and marketing expense was primarily due to increases of $28.3 million and $4.3 million in

------

employee-related expenses and marketing expense, respectively. The increase in employee-related expenses was primarily due to the Avadel Acquisition, which resulted in a 15% increase in sales and marketing-related headcount due to the addition of the LUMRYZ commercial organization. In addition, there was an increase in share-based compensation expense of approximately $13.0 million related to Avadel Shares that were accelerated and settled by us in connection with the Avadel Acquisition. See Note 3, *Business Combination* in the "Notes to Condensed Consolidated Financial Statements" in this Form 10-Q for additional information related to purchase accounting adjustments. The increase in marketing expense was primarily due to the addition of $10.5 million in costs, beginning on the Closing Date, related to marketing for LUMRYZ, partially offset by a $4.0 million decrease in media spend for ARISTADA/ARISTADA INITIO, LYBALVI and VIVITROL during the three months ended March 31, 2026.

The increase in general and administrative expense was primarily due to increases of $32.8 million, $18.7 million and $5.2 million in expenses related to the Avadel Acquisition, employee-related expenses and professional service fees, respectively. Expenses related to the Avadel Acquisition included stamp duty and transaction-related advisory fees. The increase in employee-related expenses was primarily due to increases of $11.1 million and $5.6 million in labor and benefits expense and share-based compensation expense, respectively. The increase in labor and benefits expense was primarily due to an increase in severance expense of $5.6 million related to the Avadel Acquisition, and a 15% increase in general and administrative-related headcount. The increase in share-based compensation expense was primarily due to the recognition of incremental share-based compensation expense following the modification of certain equity awards and to Avadel Shares that were accelerated and settled by us in connection with the Avadel Acquisition. The increase in professional service fees was primarily due to an increase in legal fees and expenses incurred in connection with the Avadel Acquisition.

*Other (Expense) Income, Net*

---

| | | | |
|:---|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** |  |
| **(In millions)** | **2026** | **2025** | **Change** |
| Interest income | $8.5 | $10.1 | $(1.6) |
| Interest expense | (20.9) |  | (20.9) |
| Other (expense) income, net | (1.3) | 1.6 | (2.9) |
| &nbsp;&nbsp;&nbsp;Total other (expense) income, net | $(13.7) | $11.7 | $(25.4) |

---

Interest income consists of interest earned on our cash and available-for-sale investments. Interest expense consists primarily of $7.7 million of financing costs related to Bridge Credit Agreement through the Closing Date of the Avadel Acquisition and $12.8 million of interest incurred on the Facilities. See Note 12, *Long-Term Debt* in the "Notes to Condensed Consolidated Financial Statements" in this Form 10-Q for additional information regarding the Bridge Credit Agreement and the Facilities.

*Income Tax Provision*

---

| | | | |
|:---|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** |  |
| **(In millions)** | **2026** | **2025** | **Change** |
| Income tax provision | $4.6 | $3.0 | $1.6 |

---

The income tax provision during the three months ended March 31, 2026 was primarily attributable to taxes on income earned in the U.S. The income tax provision during the three months ended March 31, 2025 was primarily attributable to taxes on income earned in Ireland.

------

**Liquidity and Financial Condition**

Our financial condition is summarized as follows:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **March 31, 2026** | **March 31, 2026** | **March 31, 2026** | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** |
| **(In millions)** | **U.S.** | **Ireland** | **Total** | **U.S.** | **Ireland** | **Total** |
| Cash and cash equivalents | $80.8 | $270.8 | $351.6 | $129.1 | $259.5 | $388.6 |
| Restricted cash |  |  |  |  | 731.2 | 731.2 |
| Investments—short-term | 159.8 | 0.5 | 160.3 | 199.1 | 0.5 | 199.6 |
| Investments—long-term | 26.4 |  | 26.4 | 0.1 |  | 0.1 |
| Total cash, restricted cash and investments | $267.0 | $271.3 | $538.3 | $328.3 | $991.2 | $1319.5 |

---

At March 31, 2026 our investments consisted of the following:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  |  | **Gross** | **Gross** |  |  |
|  | **Amortized** | **Unrealized** | **Unrealized** | **Allowance for** | **Estimated** |
| **(In millions)** | **Cost** | **Gains** | **Losses** | **Credit Losses** | **Fair Value** |
| Investments—short-term available-for-sale | $160.1 | $0.3 | $(0.1) | $— | $160.3 |
| Investments—long-term available-for-sale | 26.3 |  | (0.1) |  | 26.2 |
| Investments—long-term held-to-maturity | 0.1 |  |  |  | 0.1 |
| Total | $186.5 | $0.3 | $(0.2) | $— | $186.6 |

---

*Sources and Uses of Cash*

We used $165.7 million and generated $98.8 million of cash from operating activities during the three months ended March 31, 2026 and 2025, respectively. We expect that our existing cash, cash equivalents, restricted cash and investments will be sufficient to finance our anticipated working capital and other cash requirements, including debt services and capital expenditures, for at least the twelve months following the date from which our financial statements were issued. Subject to market conditions, interest rates and other factors, we may pursue opportunities to obtain financing in the future, including debt and equity offerings, corporate collaborations, bank borrowings, arrangements relating to assets or other financing methods or structures.

Our investment objectives are, first, to preserve liquidity and conserve capital and, second, to generate investment income. We mitigate credit risk in our cash reserves by maintaining a well-diversified portfolio that limits the amount of investment exposure as to institution, maturity and investment type. Our available-for-sale investments consist primarily of short and long-term U.S. government and agency debt securities and corporate debt securities. Our held-to-maturity investments consist of investments that are held as collateral under certain letters of credit related to certain of our lease agreements.

We classify available-for-sale investments in an unrealized loss position that do not mature within 12 months as long-term investments. We have the intent and ability to hold these investments until recovery, which may be at maturity, and it is more-likely-than-not that we would not be required to sell these securities before recovery of their amortized cost.

We have no off-balance sheet arrangements that are reasonably likely to have a material effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources in the next 12 months.

Information about our cash flows, by category, is presented in the accompanying condensed consolidated statements of cash flows. The following table summarizes our cash flows for the three months ended March 31, 2026 and 2025:

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| **(In millions)** | **2026** | **2025** |
| Cash, cash equivalents and restricted cash, beginning of period | $1119.8 | $291.1 |
| &nbsp;&nbsp;&nbsp;Cash flows (used in) provided by operating activities | (165.7) | 98.8 |
| &nbsp;&nbsp;&nbsp;Cash flows (used in) provided by investing activities | (2077.0) | 9.1 |
| &nbsp;&nbsp;&nbsp;Cash flows provided by financing activities | 1474.5 | 0.8 |
| Cash, cash equivalents and restricted cash, end of period | $351.6 | $399.8 |

---

*Operating Activities* 

------

Cash flows provided by operating activities represent the cash receipts and disbursements related to all of our activities other than investing and financing activities. Operating cash flow is derived by adjusting our net income for non-cash operating items such as depreciation, amortization and share-based compensation and changes in operating assets and liabilities, which reflect timing differences between the receipt and payment of cash associated with transactions and when they are recognized in our results of operations.

Cash flows used in operating activities for the three months ended March 31, 2026 were $165.7 million and primarily consisted of net loss of $66.5 million, adjusted for non-cash items, including share-based compensation of $36.3 million, depreciation and amortization of $19.4 million, amortization of inventory step-up of $12.7 million, deferred income taxes of $8.8 million and changes in working capital of $160.3 million.

Cash flows provided by operating activities for the three months ended March 31, 2025 were $98.8 million and primarily consisted of net income of $22.5 million, adjusted for non-cash items, including share-based compensation of $22.8 million, depreciation and amortization of $7.4 million, deferred income taxes of $2.5 million and changes in working capital of $43.3 million.

*Investing Activities* 

Cash flows used in investing activities for the three months ended March 31, 2026 were primarily due to the completion of the Avadel Acquisition and the purchase of $4.1 million of property, plant and equipment, partially offset by $12.2 million in net sales of investments. Total cash consideration paid on the Closing Date was $2,199.2 million. We accounted for the Avadel Acquisition as a business combination and recognized $2,085.1 million of assets acquired, net of liabilities assumed and cash transferred as an investing activity during the three months ended March 31, 2026.

Cash flows provided by investing activities for the three months ended March 31, 2025 were primarily due to $17.5 million in net sales of investments, partially offset by the purchase of $10.1 million of property, plant and equipment.

*Financing Activities* 

Cash flows provided by financing activities for the three months ended March 31, 2026 were primarily due to $1,511.6 million in net proceeds from borrowings under the Facilities in connection with the Avadel Acquisition and $15.7 million of cash that we received upon exercises of employee stock options, partially offset by $27.7 million (exclusive of any fees, commissions or other related expenses) used to repurchase our ordinary shares under the Repurchase Program and $23.4 million of employee taxes paid related to the net share settlement of equity awards.

Cash flows provided by financing activities for the three months ended March 31, 2025 were primarily due to $29.5 million of cash that we received upon exercises of employee stock options, partially offset by $28.8 million of employee taxes paid related to the net share settlement of equity awards.

*Debt*

On February 12, 2026, in connection with the Avadel Acquisition, we entered into the Credit Agreement, which provides for (i) a TLA Facility in an aggregate principal amount of up to $750.0 million and (ii) a TLB Facility in an aggregate principal amount of up to $775.0 million. The TLA Facility matures on February 12, 2031, and the TLB Facility matures on August 12, 2031. On the Closing Date, we borrowed the full $1.525 billion available under the Facilities.

For additional details regarding our outstanding indebtedness, see Note 12, *Long-Term Debt* in the "Notes to Condensed Consolidated Financial Statements" in this Form 10-Q.

Also on February 12, 2026, in connection with completion of the Avadel Acquisition and our entry into the Credit Agreement, we terminated the Bridge Credit Agreement originally entered into in order to fund the Avadel Acquisition, as the commitments under the Credit Agreement, together with our cash on hand as of the Closing Date, were sufficient to fund the Avadel Acquisition.

*Critical Accounting Estimates*

The discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of our financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from these estimates under different conditions or using different

------

assumptions.

See the "Critical Accounting Estimates" section in "Part II, Item 7—Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Annual Report for a discussion of our critical accounting estimates. See below for a discussion of additions to our critical accounting estimates since December 31, 2025.

*Contingent Consideration*

We record contingent consideration we may owe related to a business combination at fair value on the acquisition date. We estimate the fair value of contingent consideration through valuation models that incorporate a probability-weighted discounted cash flow model related to the achievement of a certain specified milestone. We revalue our contingent consideration each reporting period, with changes in the fair value of contingent consideration recognized within the consolidated statements of operations and comprehensive (loss) income. Changes in the fair value of contingent consideration can result from changes to one or multiple assumptions, including adjustments to the discount rates, changes in the assumed achievement and timing of any such specified milestone and changes in the assumed probability associated with regulatory approval.

The period over which we discount contingent consideration is based on the current development stage of the product candidate, the specific development plan for such product candidate adjusted for the probability of completing the development step, and the date on which contingent payments may be triggered. In estimating the probability of success, we utilize data regarding similar milestone events from several sources, including industry studies and our own experience. These fair value measurements are based on significant inputs not observable in the market. Significant judgment is employed in determining the appropriateness of these assumptions at the acquisition date and for each subsequent reporting period. Accordingly, changes in assumptions described above could have a material impact on the increase or decrease in the fair value of contingent consideration recorded in any given period.

At March 31, 2026, our contingent consideration related to the CVR Milestone issued in connection with the Avadel Acquisition. The fair value of the contingent consideration was determined as follows:

&nbsp;&nbsp;&nbsp;&nbsp;•As part of consideration for the Avadel Acquisition, holders of Avadel Shares as of the Closing Date are entitled to receive a potential additional aggregate cash payment of $165.7 million, or $1.50 per Avadel Share, upon achievement of the CVR Milestone.

&nbsp;&nbsp;&nbsp;&nbsp;•The fair value of the contingent consideration was estimated by applying a discount factor, calculated based on the likelihood of achievement of the CVR Milestone, from the expected time the milestone occurs to the end of the reporting period, to the estimated probability of success. We expect the CVR Milestone to occur no later than the end of 2028 and used a discount rate of 5.47%;

Significant judgment was employed in determining the appropriateness of these assumptions at the Closing Date. Accordingly, changes in assumptions described above could have a material impact on the increase or decrease in the fair value of contingent consideration we record in any given period. In accordance with the accounting standard for fair value measurements, the fair value of the contingent consideration has been classified as a Level 3 liability as its fair value is based on significant inputs not observable in the market.

*Valuation of Intangible Assets*

Our intangible assets consist primarily of IP related to the existing commercial product and IPR&D product candidates that we acquired as part of the Avadel Acquisition. When significant identifiable intangible assets are acquired, we engage an independent third-party valuation firm to assist in determining the fair values of these assets as of the acquisition date. Discounted cash flow models are typically used in these valuations, which require the use of significant estimates and assumptions, including but not limited to:

&nbsp;&nbsp;&nbsp;&nbsp;•estimating the timing of and expected costs to complete the in-process project;

&nbsp;&nbsp;&nbsp;&nbsp;•projecting regulatory approvals;

&nbsp;&nbsp;&nbsp;&nbsp;•estimating future cash flows from product sales resulting from completed products and in-process project; and

&nbsp;&nbsp;&nbsp;&nbsp;•developing appropriate discount rates and probability rates by project.

------

We believe the fair values assigned to the intangible assets acquired are based upon reasonable estimates and assumptions given available facts and circumstances as of the acquisition date. If these projects are not successfully developed, the sales and profitability of the Company may be adversely affected in future periods. Additionally, the value of the acquired intangible assets may become impaired. We believe that the foregoing assumptions used in the IPR&D analysis were reasonable as of the acquisition date. No assurance can be given, however, that the underlying assumptions used to estimate expected product sales, development costs or profitability, or the events associated with such products, will transpire as estimated.

*New Accounting Standards*

See the "New Accounting Pronouncements" section in Note 2, *Summary of Significant Accounting Policies* in the "Notes to Condensed Consolidated Financial Statements" in this Form 10-Q for discussion of certain recent accounting standards applicable to us.

**Item 3. *Quantitative and Qualitative Disclosures About Market Risk***

Market risks related to our investment portfolio, and the ways we manage such risks, are summarized in "Part II, Item 7A—Quantitative and Qualitative Disclosures About Market Risk" in our Annual Report. We regularly review our marketable securities holdings and shift our investment holdings to those that best meet our investment objectives, which are to preserve capital, provide sufficient liquidity to satisfy operating requirements and generate investment income. Apart from such adjustments to our investment portfolio, there have been no material changes to our market risks since December 31, 2025, and we do not anticipate any near-term changes in the nature of our market risk exposures or in our management's objectives and strategies with respect to managing such exposures.

We are exposed to non-U.S. currency exchange risk related primarily to royalty revenues that we receive on certain of our products, partially offset by certain operating costs arising from expenses and payables in connection with our Irish operations that are settled predominantly in euro. These non-U.S. currency exchange rate risks are summarized in "Part II, Item 7A—Quantitative and Qualitative Disclosures About Market Risk" in our Annual Report. There has been no material change in our assessment of our sensitivity to non-U.S. currency exchange rate risk since December 31, 2025.

At March 31, 2026, our borrowings consisted of $1.525 billion outstanding under the Facilities. The TLA Facility matures on February 12, 2031; the TLB Facility matures on August 12, 2031. The Facilities bear interest at the one-, three- or six-month SOFR rate of our choosing plus a credit spread adjustment applicable to the interest period and an applicable margin of 2.75%. We are currently using the three-month SOFR rate, which was 3.68% at March 31, 2026. A 10% increase in this rate would increase the amount of interest we would expect to pay from April 1, 2026 through December 31, 2026 by $4.4 million. See Note 12, *Long-Term Debt* in the "Notes to Condensed Consolidated Financial Statements" in this Form 10-Q for additional information related to the Facilities.

**Item 4. *Controls and Procedures***

*a) Evaluation of Disclosure Controls and Procedures*

Our management has evaluated, with the participation of our principal executive officer and principal financial officer, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of March 31, 2026. Based upon that evaluation, our principal executive officer and principal financial officer each concluded that, as of the end of the period covered by this report, our disclosure controls and procedures were effective to provide reasonable assurance that (a) the information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and (b) such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

*b) Change in Internal Control Over Financial Reporting*

During the three months ended March 31, 2026, there have been no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

------

**PART II. OTHER INFORMATION**

**Item 1. *Legal Proceedings***

For information regarding legal proceedings, see the discussion of legal proceedings in Note 18, *Commitments and Contingent Liabilities* in the "Notes to Condensed Consolidated Financial Statements" in this Form 10-Q, which discussion is incorporated into this Part II, Item 1 by reference.

**Item 1A. Risk Factors**

For a discussion of our risk factors, see "Part I, Item 1A—Risk Factors" in our Annual Report.

**Item 2. *Unregistered Sales of Equity Securities and Use of Proceeds***

The following table summarizes purchases of our ordinary shares made by or on behalf of us or any of our affiliated purchasers, as defined in Rule 10b-18(a)(3) under the Exchange Act, during the three months ended March 31, 2026:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Period** | **Total Number of Ordinary Shares Purchased<br>(a)** |  | **Average Price Paid per Ordinary Share<br>(b)** | **Total Number of Ordinary Shares Purchased as Part of Publicly Announced Program<br>(c)**<sup>(2)</sup> |  | **Approximate Dollar Value (in millions) of Ordinary Shares that May Yet Be Purchased Under the Program <br>(d)**<sup>(2)</sup> |
| January 1, 2026 – January 31, 2026 | 723 |  | $28.53 |  |  | $200.0 |
| February 1, 2026 – February 28, 2026 | 729668 |  | 32.08 |  |  | 200.0 |
| March 1, 2026 – March 31, 2026 | 996040 |  | 27.85 | 995494 |  | 172.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Totals | 1726431 | (1) | $29.62 | 995494 | (1) |  |

---

------

&nbsp;&nbsp;&nbsp;&nbsp;(1)The difference between the total number of ordinary shares purchased shown in column (a) and the total number of ordinary shares purchased as part of the publicly announced Repurchase Program shown in column (c) consists of 730,937 ordinary shares acquired during the three months ended March 31, 2026 to satisfy withholding tax obligations related to the vesting of equity awards.

&nbsp;&nbsp;&nbsp;&nbsp;(2)In February 2024, we announced approval by our board of directors of the Repurchase Program, which authorized the repurchase of our ordinary shares in an aggregate amount of up to $400.0 million (exclusive of any fees, commissions or other expenses related to such repurchases) from time to time. The specific timing and amounts of repurchases under the Repurchase Program will depend on a variety of factors, including but not limited to ongoing assessments of our needs, alternative investment opportunities, the market price of our ordinary shares and general market conditions. The Repurchase Program has no set expiration date and may be suspended or discontinued at any time.

**Item 5. *Other Information*** 

During the three months ended March 31, 2026, the following contracts, instructions or written plans for the purchase or sale of the Company's securities that are or were intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act (each, a "Rule 10b5-1 plan") were adopted by officers (as defined in Rule 16a-1(f) under the Exchange Act) and directors of the Company: (i) on March 11, 2026, Christopher Wright, M.D., Ph.D., a director of the Company, adopted a Rule 10b5-1 plan providing for the sale of up to 2,000 ordinary shares of the Company that may be obtained from the vesting of restricted stock unit awards; this plan is scheduled to expire on December 31, 2026; and (ii) on March 12, 2026, Richard Pops, our Chairman and Chief Executive Officer, adopted a Rule 10b5-1 plan providing for the sale of up to 203,999 ordinary shares of the Company that may be obtained from the exercise of expiring stock options; this plan is scheduled to expire on February 17, 2027. During the three months ended March 31, 2026, no other directors or officers of the Company adopted or terminated a Rule 10b5-1 plan or a trading plan not intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.

------

**Item 6. *Exhibits***

The following exhibits are filed or furnished as part of this Form 10-Q:

**EXHIBIT INDEX**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description of Exhibit** |
| &nbsp;&nbsp;&nbsp;&nbsp;2.1 § | [<u>Transaction Agreement, dated as of October 22, 2025 by and among Alkermes plc and Avadel</u>](https://www.sec.gov/Archives/edgar/data/1520262/000119312525245852/d946576dex21.htm)<br>[<u>Pharmaceuticals plc (incorporated by reference to Exhibit 2.1 to the Alkermes plc Current Report on</u>](https://www.sec.gov/Archives/edgar/data/1520262/000119312525245852/d946576dex21.htm)<br>[<u>Form 8-K (File No. 001-35299) filed on October 22, 2025).</u>](https://www.sec.gov/Archives/edgar/data/1520262/000119312525245852/d946576dex21.htm) |
| &nbsp;&nbsp;&nbsp;&nbsp;2.1A | [<u>Amendment No. 1 to the Transaction Agreement, dated as of November 18, 2025, by and between Alkermes plc and Avadel Pharmaceuticals plc (incorporated by reference to Exhibit 2.1 to the Alkermes plc Current Report on Form 8-K (File No. 001-35299) filed on November 19, 2025).</u>](https://www.sec.gov/Archives/edgar/data/1520262/000119312525286909/d858713dex21.htm) |
| &nbsp;&nbsp;&nbsp;&nbsp;2.1B | [<u>Appendix III to the Rule 2.7 Announcement, dated as of October 22, 2025 (Conditions Appendix) (incorporated by reference to Exhibit 2.2 to the Alkermes plc Current Report on Form 8-K (File No. 001-35299) filed on October 22, 2025).</u>](https://www.sec.gov/Archives/edgar/data/1520262/000119312525245852/d946576dex22.htm) |
| &nbsp;&nbsp;&nbsp;&nbsp;10.1 § | [<u>Credit Agreement, dated as of February 12, 2026, by and among Alkermes plc, as the TopCo Borrower, Alkermes, Inc., as the U.S. Borrower, Alkermes Finance LLC, as the U.S. Co-Borrower, JPMorgan Chase Bank, N.A., as Administrative Agent, Joint Lead Arranger and Joint Bookrunner, Bank of America, N.A., as Syndication Agent (incorporated by reference to Exhibit 10.1 to the Alkermes plc Current Report on Form 8-K (File No. 001-35299) filed on February 12, 2026).</u>](https://www.sec.gov/Archives/edgar/data/1520262/000119312526047682/d43532dex101.htm) |
| &nbsp;&nbsp;&nbsp;&nbsp;10.2 #† | [<u>Letter agreement, dated February 24, 2026, by and between Alkermes plc and Richard F. Pops.</u>](alks-ex10_2.htm) |
| &nbsp;&nbsp;&nbsp;&nbsp;31.1 # | [<u>Rule 13a-14(a)/15d-14(a) Certification.</u>](alks-ex31_1.htm) |
| &nbsp;&nbsp;&nbsp;&nbsp;31.2 # | &nbsp;&nbsp;[<u>Rule 13a-14(a)/15d-14(a) Certification.</u>](alks-ex31_2.htm) |
| &nbsp;&nbsp;&nbsp;&nbsp;32.1 ‡ | [<u>Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</u>](alks-ex32_1.htm) |
| &nbsp;&nbsp;&nbsp;&nbsp;101.SCH # | &nbsp;&nbsp;Inline XBRL Taxonomy Extension Schema Document with Embedded Linkbase Documents. |
| &nbsp;&nbsp;&nbsp;&nbsp;104 # | Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibit 101). |

---

------

# Filed herewith.

‡ Furnished herewith.

† Indicates a management contract or any compensatory plan, contract or arrangement.

§Schedules and similar attachments to this exhibit have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company undertakes to furnish copies of any omitted schedules and similar attachments upon request by the SEC.

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | ALKERMES PLC | ALKERMES PLC |
|  | (Registrant) | (Registrant) |
|  | By: | &nbsp;&nbsp;&nbsp;&nbsp;/s/ Richard F. Pops |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;Richard F. Pops |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;Chairman and Chief Executive Officer |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;(Principal Executive Officer) |
|  | By: | &nbsp;&nbsp;&nbsp;&nbsp;/s/ Joshua Reed |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;Joshua Reed |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;Senior Vice President, Chief Financial Officer |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;(Principal Financial Officer) |
| Date: May 5, 2026 |  |  |

---

------

## Exhibit 10.2

**Exhibit 10.2**

February 24, 2026

Richard F. Pops<br>Connaught House, 1 Burlington Road

Dublin 4, Ireland D04 C5Y6

Dear Richard:

On behalf of Alkermes plc (the "Company") and its Board of Directors (the "Board"), I want to thank you for your many years of service to the Company, during which you have demonstrated remarkable leadership and have made immeasurable contributions to the Company. We appreciate your willingness to provide continued support and expertise to the Company following your retirement as our Chief Executive Officer by providing advisory services and continuing to serve on the Board.

This letter agreement ("Agreement") supplements the terms of the Employment Agreement by and between you and Alkermes, Inc., a subsidiary of the Company, entered into and effective as of December 12, 2007, as amended (the "Employment Agreement"), as follows:

**Term and Duties.** Your retirement as Chief Executive Officer will become effective at 11:59pm Eastern Time on July 31, 2026 (the "Transition Date"). Until the Transition Date, and unless otherwise stated herein, your employment, including the payment of your salary and bonus, will be governed by the Employment Agreement. Following the Transition Date, you agree to serve as non-employee Senior Advisor to the Company ("Senior Advisor") through December 31, 2026 (the "Senior Advisor Service Term"), reporting directly to the incoming Chief Executive Officer. In addition, following the Transition Date, you shall also serve as non-executive chairman of the Board ("Chairman") until such date as determined by the Board. Your service as Senior Advisor may be terminated for any reason prior to the expiration of the Senior Advisor Service Term by the Company or by you; provided, however, the Company agrees that it shall not terminate your service as Senior Advisor other than for Cause (as defined in the Employment Agreement).

In your role as Senior Advisor, you agree to provide transition and other related services to the Company to provide an effective transition of your executive responsibilities to the Company's incoming Chief Executive Officer, as requested by the incoming Chief Executive Officer. In addition, as requested by the incoming Chief Executive Officer, (i) you will continue to be involved in and support an orderly transition of services and relationships relating to Federal policy matters, including but not limited to your involvement in industry trade associations, in each case, coordinating with the incoming Chief Executive Officer and (ii) you will be available to consult with the incoming Chief Executive Officer on other management activities. You and the Company agree that based on the anticipated level of services that you will perform for the Company during the Senior Advisor Service Term, you are not expected to experience a "separation from service" under Section 409A of the Internal Revenue Code of 1986, as amended, during the Senior Advisor Service Term.

As Chairman, you will perform the duties normally assigned to a non-executive chairman of the Board of a publicly-traded corporation, which will include, but not be limited to, (i) chairing meetings of the Board and the Company's shareholders, (ii) coordinating with the incoming Chief Executive Officer, the Lead Independent Director and other members of the Board to schedule meetings of the Board and prepare the agenda for such meetings, (iii) consulting with and supporting the incoming Chief Executive Officer on the Company's strategy, including short- and long-range planning activities and growth strategies, and (iv) assisting in communications with investors, analysts and public relations, as requested by the incoming Chief Executive Officer.

Upon the expiration of the Senior Advisor Service Term (or the earlier termination of your advisory services engagement), you shall cease serving as Senior Advisor. Subject to the Company's governing documents and compliance with applicable law and fiduciary duties, the Board will nominate you to the Board and recommend to the shareholders that you serve as a member of the Board through the Company's 2027 Annual General Meeting of

------

Shareholders. If elected by the Company's shareholders at the 2026 Annual General Meeting of Shareholders, you shall continue to serve as a member of the Board through the Company's 2027 Annual General Meeting of Shareholders (the "Board Services Term").

Except as set forth in this Agreement, upon your retirement as Chief Executive Officer, you shall be deemed to have resigned, without any further action by you, from any and all officer, director and other positions that you, immediately prior to such termination, (i) held with the Company or any of its affiliates (except for your role as a director of the Board and member of the Financial Operating Committee of the Company) or (ii) held with any other entities (other than the industry trade associations related to your advisory services) at the direction of, or as a result of your affiliation with, the Company or any of its affiliates. If for any reason this Agreement is deemed to be insufficient to effectuate such resignations or this Agreement conflicts with the rules of any of the entities on which you serve as an officer or director, then you shall, upon the Company's request, execute any documents or instruments that the Company may deem necessary or desirable to effectuate such resignations.

**Compensation.** 

During the Senior Advisor Service Term and your term of service as the Chairman:

• you will receive a monthly cash retainer of $75,000 for your service as Senior Advisor during the Senior Advisor Service Term, payable in accordance with the normal payment practices of the Company or its affiliates for this type of consultancy role;

• you will receive an annual cash bonus for fiscal year 2026, payable at the target level (100%), pro-rated to an amount equal to seven-twelfths (7/12) of such bonus amount to reflect your seven months of service as Chief Executive Officer during fiscal year 2026. Such bonus shall be paid at the same time bonuses are paid to the Company's other executive officers (but in any event, no later than 2 1/2 months following the conclusion of fiscal year 2026);

• you will receive a time-based restricted stock unit award for fiscal year 2026, with a grant value equal to $2,687,500.00, which is consistent with your fiscal year 2025 annual equity incentive award, pro-rated to the amount equal to twelve-forty eighths (12/48) of such grant value to reflect your services during 2026 through the Senior Advisor Service Term. Such equity incentive award shall cliff vest on December 31, 2026, subject to your continued service on such date or as otherwise set forth in the underlying award certificate;

• you will receive a payout of your accrued but unused vacation through July 31, 2026, in accordance with the Company's vacation policy practices for departing employees then in effect; and

• while serving as Chairman, you will receive a separate Chairman cash retainer fee based on an annual retainer of $40,000 and pro-rated for your service from the Transition Date through the end of your service as Chairman.

In recognition of your continued service on the Board and to induce your entry into this Agreement and to retain your continued services, during your service on the Board:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•your outstanding equity awards will continue to vest based on your continued service relationship with the Company through the end of the Board Services Term;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•you will be eligible to participate in the Company's compensation program for non-employee directors on the same terms and conditions as the other non-employee directors; provided, however, you will not be eligible to receive any pro-rated annual non-employee director equity grant or any new director equity grant;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•upon the expiration of the Board Services Term, (a) the portion of your outstanding, unvested time-based stock options that are scheduled to vest during the 21-month period following the end of the Board Services

------

Term, i.e., through February 28, 2029 ("Post-Termination Vesting Period") shall accelerate and become vested upon the expiration of the Board Services Term, (b) your outstanding, unvested performance-based stock options shall remain outstanding during the Post-Termination Vesting Period and shall vest, if at all, to the extent the underlying performance goal(s) are achieved (but shall expire in all events at the earlier of the expiry of the Post-Termination Vesting Period and the expiration date set forth in such options) and (c) your 2025 performance-based restricted stock unit awards that are scheduled to vest during the Post-Termination Vesting Period shall remain outstanding and shall vest, if at all, based on actual performance during the underlying performance period, notwithstanding any provision of the awards to the contrary; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•upon the expiration of the Board Services Term, the post-termination exercise periods of your outstanding, vested stock options shall be extended to the earlier of (a) the end of the Post-Termination Vesting Period; and (b) the original expiration date of the applicable stock option;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Notwithstanding the foregoing, in the event of a Change in Control (as defined in the Employment Agreement) or a Sale Event (as defined in the Company's 2018 Stock Option and Incentive Plan, as amended) (i) prior to the expiration of the Board Services Term, your outstanding equity awards will be treated no less favorably than as set forth in Section 3(d)(ii) of the 2018 Plan, and (ii) following the expiration of the Board Services Term (including as a result of your termination of Board service in connection with a Change in Control or Sale Event) and prior to the end of the Post-Termination Vesting Period, your outstanding equity awards will become fully vested as of immediately prior to the closing of such Change in Control or Sale Event, with the achievement of the performance-based vesting conditions determined in accordance with the terms of such award(s); provided, that you shall be treated no less favorable than other holders of such awards.

For the avoidance of doubt, (i) any of your outstanding, unvested equity awards that are scheduled to vest beyond the Post-Termination Vesting Period shall terminate in accordance with their terms upon the expiration of the Board Services Term, (ii) you shall not be entitled to any additional compensation for your services following the Transition Date, except as set forth in this Agreement or as otherwise approved by the Compensation Committee of the Board, (iii) for the compensation you receive as Senior Advisor and a non-employee member of the Board, you shall be responsible for all tax obligations as an independent contractor, and the Company shall not withhold any amounts from such payments for taxes and (iv) following the Transition Date, you shall not be eligible to participate in any of the employee benefits provided by the Company or any of its affiliates, subject to your ability to elect COBRA continuation coverage with respect to the Company's health plans.

**Non-Solicitation Covenant**. You agree that, during your service as an employee, Senior Advisor and/or service as a director to the Company and thereafter for a period of two (2) years following the final termination of your service relationship for any reason, you shall not, directly or indirectly, on your own behalf or on behalf of or in conjunction with any other person or entity: (a) solicit, recruit, induce, encourage, or attempt to solicit, recruit, induce, or encourage any individual who is or was employed by the Company or any of its affiliates at any time during the twelve (12) months preceding the end of your employment to terminate his or her employment or other service relationship with the Company or any of its affiliates; (b) hire, employ, engage, or attempt to hire, employ, or engage (whether as an employee, consultant, independent contractor, partner, or otherwise) any such individual; (c) solicit, induce, encourage, or attempt to solicit, induce, or encourage any customer, client, vendor, supplier, licensee, or other business relation of the Company or any of its affiliates (including any prospective customer or business relation with whom you had material contact or about whom you obtained confidential information during the last twenty-four (24) months of your employment) to terminate, diminish, reduce, or otherwise materially alter in a manner adverse to the Company or any of its affiliates its business relationship with the Company or any of its affiliates; or (d) assist, participate in, or facilitate any of the foregoing activities, whether as an employee, consultant, agent, owner, partner, or otherwise. Notwithstanding the foregoing, nothing herein shall prevent you from hiring, without solicitation, an individual who applies for employment as a result of a job advertisement directed to the general public.

**Acknowledgments**. You acknowledge that the provisions set forth herein are necessary and reasonable to protect the confidential and proprietary information of the Company and have been specifically negotiated between you and the Company to arrive at reasonable and narrowly-tailored restraints that will protect the Company's legitimate interests

------

in its confidential and proprietary information, without unduly burdening your ability to earn a living. You further acknowledge that a breach or threatened breach by you of your non-solicitation obligations in this Agreement will cause serious and irreparable harm to the Company for which it shall have no adequate remedy at law, and, therefore, in addition to any other rights and remedies that the Company may have, you agree that the Company, without posting any bond, shall be entitled to seek to obtain a temporary restraining order or a preliminary or permanent injunction and other equitable relief to prevent such a threatened, actual, or continuing breach. While the restrictions contained herein are considered reasonable by the parties and necessary for the protection of the legitimate business interests of the Company, it is agreed that if any such restriction is found to be void or voidable but would be valid and enforceable if some part or some parts thereof was deleted, such restriction shall apply with such modification as may be necessary to make it valid and enforceable. Each of the restrictions set forth above is intended to be entirely separate and severable and if one or more restrictions is found void or unenforceable, the validity of the remaining restrictions shall not be affected.

You further acknowledge and agree that nothing in this Agreement or in any agreement between you and the Company prohibits or limits you (or your attorney) from initiating communications directly with, responding to any inquiry from, volunteering information to, or providing testimony before the Securities and Exchange Commission (SEC), the Department of Justice, FINRA, any other self-regulatory organization, or any other governmental, law enforcement, or regulatory authority, regarding any reporting of, investigation into, or proceeding regarding suspected violations of law, and that you are not required to advise or seek permission from the Company before or after engaging in any such activity. You further acknowledge that, in connection with any such activity, you must inform such authority of the confidential nature of any confidential information that you provide, and that you are not permitted to disclose any information that is protected by the attorney-client privilege or any other privilege belonging to the Company or its affiliates, as the Company and its affiliates does not waive and intends to preserve such privileges.

**Governing Law; Arbitration**. This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts. Any dispute relating to this Agreement shall be subject to the arbitration provisions set forth in your Employment Agreement.

**Existing Employment Agreement.** You and the Company hereby acknowledge and agree that, you will waive all rights to severance pay and benefits set forth in Sections 5(b) or 6(b) of the Employment Agreement and the provisions of your Employment Agreement that survive your termination of employment shall continue in accordance with their terms. Accordingly, effective on the Transition Date, you shall not be eligible for severance under Section 5(b) of the Employment Agreement as a result of your assumption of the role of Chairman and Senior Advisor, including on account of Good Reason (as defined in the Employment Agreement). You remain eligible for the benefits in your Deed of Indemnification with the Company, dated April 28, 2020, and in your Indemnification Agreement with Alkermes, Inc., a subsidiary of the Company, dated April 28, 2020. Finally, you acknowledge that you shall continue to be bound by the covenants set forth in Section 7 of the Employment Agreement, and, to the extent of any conflict between the restrictive covenants in this Agreement and Section 7 of the Employment Agreement, the more restrictive provision shall govern.

**Attorneys' Fees**. The Company agrees to reimburse your attorneys' fees incurred in this leadership transition (up to a maximum of $60,000) and paid within 60 days following the date hereof.

Again, thank you for your many years of dedicated service to the Company and your agreement to assist the Company in its leadership transition.

---

| | |
|:---|:---|
|  | Sincerely,  |
|  | Alkermes plc |
| By: | /s/ Richard Gaynor |
| Name:  | Richard B. Gaynor, M.D. |
| Title | Director |

---

------

This letter agreement correctly reflects our understanding, and I hereby confirm my agreement to the same as of the date set forth above.

---

| |
|:---|
| /s/ Richard Pops |
| Richard F. Pops |

---

------

## Exhibit 31.1

**Exhibit 31.1**

**CERTIFICATIONS**

I, Richard F. Pops, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.I have reviewed this Quarterly Report on Form 10-Q of Alkermes plc;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| Date: May 5, 2026 | /s/ Richard F. Pops |
|  | Richard F. Pops |
|  | Chairman and Chief Executive Officer |
|  | (Principal Executive Officer) |

---

------

## Exhibit 31.2

**Exhibit 31.2**

**CERTIFICATIONS**

I, Joshua Reed, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.I have reviewed this Quarterly Report on Form 10-Q of Alkermes plc;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| Date: May 5, 2026 | /s/ Joshua Reed |
|  | Joshua Reed |
|  | Senior Vice President, Chief Financial Officer |
|  | (Principal Financial Officer) |

---

------

## Exhibit 32.1

**Exhibit 32.1**

**CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report on Form 10-Q of Alkermes plc (the "Company") for the period ended March 31, 2026 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), we, Richard F. Pops, Chairman and Chief Executive Officer of the Company, and Joshua Reed, Senior Vice President, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to our knowledge:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | |
|:---|:---|
| Date: May 5, 2026 | /s/ Richard F. Pops |
|  | Richard F. Pops |
|  | Chairman and Chief Executive Officer |
|  | (Principal Executive Officer) |
| Date: May 5, 2026 | /s/ Joshua Reed |
|  | Joshua Reed |
|  | Senior Vice President, Chief Financial Officer |
|  | (Principal Financial Officer) |

---

------